text:
Patent US4892538 - In vivo delivery of neurotransmitters by implanted, encapsulated cells - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsMethods and devices are disclosed for the delivery of a neurotransmitter from an implanted, neurotransmitter-secreting cell culture to a target region in a subject. The cell culture is maintained within a biocompatible, semipermeable membrane which permits the diffusion of the neurotransmitter therethrough...http://www.google.com/patents/US4892538?utm_source=gb-gplus-sharePatent US4892538 - In vivo delivery of neurotransmitters by implanted, encapsulated cellsAdvanced Patent SearchTry the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.Publication numberUS4892538 APublication typeGrantApplication numberUS 07/121,626Publication dateJan 9, 1990Filing dateNov 17, 1987Priority dateNov 17, 1987Fee statusPaidAlso published asCA1335715C, DE3878918D1, DE3878918T2, EP0388428A1, EP0388428B1, USRE35653, WO1989004655A1Publication number07121626, 121626, US 4892538 A, US 4892538A, US-A-4892538, US4892538 A, US4892538AInventorsPatrick Aebischer, Shelley R. Winn, Pierre M. GallettiOriginal AssigneeBrown University Research FoundationExport CitationBiBTeX, EndNote, RefManPatent Citations (11), Non-Patent Citations (24), Referenced by (653), Classifications (44), Legal Events (7) External Links: USPTO, USPTO Assignment, EspacenetIn vivo delivery of neurotransmitters by implanted, encapsulated cells
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS3093831 *Oct 22, 1959Jun 18, 1963Jordan Gerhard Paul WilhelmArtificial glandUS4241187 *Mar 27, 1979Dec 23, 1980United States Of AmericaMethod and apparatus for cell and tissue cultureUS4352883 *Mar 28, 1979Oct 5, 1982Damon CorporationEncapsulation of biological materialUS4353888 *Dec 23, 1980Oct 12, 1982Sefton Michael VEncapsulation of live animal cellsUS4378016 *Jul 15, 1981Mar 29, 1983Biotek, Inc.Artificial endocrine gland containing hormone-producing cellsUS4391909 *May 1, 1981Jul 5, 1983Damon CorporationMicrocapsules containing viable tissue cellsUS4402694 *Jul 16, 1981Sep 6, 1983Biotek, Inc.Body cavity access device containing a hormone sourceUS4686098 *May 14, 1984Aug 11, 1987Merck & Co., Inc.Encapsulated mouse cells transformed with avian retrovirus-bovine growth hormone DNA, and a method of administering BGH in vivoEP0147939A2 *Nov 14, 1984Jul 10, 1985JOHNSON & JOHNSONImplantable module for gylcemia regulationEP0161640A2 *May 10, 1985Nov 21, 1985Merck & Co., Inc.Encapsulated mouse cells transformed with avian retrovirus-bovine growth hormone DNA, and a method of administering BGH in vivoEP0213908A2 *Aug 22, 1986Mar 11, 1987Hana Biologics, Inc.Transplantable artificial tissue and process* Cited by examinerNon-Patent CitationsReference1Annals of the N.Y. Academy of Sciences, "Cell and Tissue Transplantation into the Adult Brain", vol. 495, pp. 306-333, 473-496, 581-597, 598-605, 606-622, 786-791, 804-806, Jun. 30, 1987.2Annals of the N.Y. Academy of Sciences, "Hope for a New Neurology", pp. 105-126, vol. 457, Dec. 31, 1985.3 *Annals of the N.Y. Academy of Sciences, Cell and Tissue Transplantation into the Adult Brain , vol. 495, pp. 306 333, 473 496, 581 597, 598 605, 606 622, 786 791, 804 806, Jun. 30, 1987.4 *Annals of the N.Y. Academy of Sciences, Hope for a New Neurology , pp. 105 126, vol. 457, Dec. 31, 1985.5Bjorklund et al., "Cross-Species Neural Grafting in a Rat Model of Parkinsons's Disease", Nature, vol. 298, pp.652-654, Aug. 12, 1982.6 *Bjorklund et al., Cross Species Neural Grafting in a Rat Model of Parkinsons s Disease , Nature, vol. 298, pp.652 654, Aug. 12, 1982.7 *Brundin et al., Exp. Brain Res.(1985) 60:204 208.8Brundin et al., Exp. Brain Res.(1985) 60:204-208.9 *Calne et al., Bri. Med. J. (1974) 4:442 444.10Calne et al., Bri. Med. J. (1974) 4:442-444.11 *Calne et al., The Lancet (1969), Nov. 8, pp. 973 976.12Calne et al., The Lancet (1969), Nov. 8, pp. 973-976.13Dichter, "The Epilepsies and Convulsive Disorders," in Principals of Internal Medicine (Harrison et al., eds.) Tenth Addition, 1983, pp. 2125-2127.14 *Dichter, The Epilepsies and Convulsive Disorders, in Principals of Internal Medicine (Harrison et al., eds.) Tenth Addition, 1983, pp. 2125 2127.15 *Freed et al., Nature (1981) 292:351 352.16Freed et al., Nature (1981) 292:351-352.17 *Hefti et al., Brain Res. (1985) 348:283 288.18Hefti et al., Brain Res. (1985) 348:283-288.19 *Perlow et al., Science (1979) 204:643 647.20Perlow et al., Science (1979) 204:643-647.21 *Stenaas and Stenaas, Acta. Neuropath. (Berl.) (1978) 41:145 155.22Stenaas and Stenaas, Acta. Neuropath. (Berl.) (1978) 41:145-155.23 *Sun et al., Diabetes, vol. 26, No. 12, pp. 1136 1139, Dec. 1977.24Sun et al., Diabetes, vol. 26, No. 12, pp. 1136-1139, Dec. 1977.* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS5011472 *Sep 6, 1988Apr 30, 1991Brown University Research FoundationImplantable delivery system for biological factorsUS5182111 *Jun 28, 1991Jan 26, 1993Boston University Research FoundationIn vivo delivery of active factors by co-cultured cell implantsUS5222982 *Feb 25, 1992Jun 29, 1993Ommaya Ayub KSpinal fluid driven artificial organUS5232712 *Jun 28, 1991Aug 3, 1993Brown University Research FoundationExtrusion apparatus and systemsUS5314471 *Apr 1, 1992May 24, 1994Baxter International Inc.Tissue inplant systems and methods for sustaining viable high cell densities within a hostUS5324518 *Mar 30, 1992Jun 28, 1994Biosynthesis, Inc.Implantable structure for containing substances for delivery to a bodyUS5344454 *Apr 1, 1992Sep 6, 1994Baxter International Inc.Closed porous chambers for implanting tissue in a hostUS5383873 *Dec 9, 1992Jan 24, 1995Regents Of The University Of MinnesotaSmooth muscle chemical pacemakerUS5385582 *Aug 9, 1993Jan 31, 1995Ommaya; Ayub K.Spinal fluid driven artificial organUS5389535 *Dec 17, 1993Feb 14, 1995Brown University Research FoundationMethod of encapsulating cells in a tubular extrudateUS5418154 *Dec 24, 1992May 23, 1995Brown University Research FoundationMethod of preparing elongated seamless capsules containing biological materialUS5428123 *Apr 23, 1993Jun 27, 1995The Polymer Technology GroupCopolymers and non-porous, semi-permeable membrane thereof and its use for permeating molecules of predetermined molecular weight rangeUS5453278 *Jan 28, 1994Sep 26, 1995Baxter International Inc.Laminated barriers for tissue implantsUS5474547 *Dec 16, 1993Dec 12, 1995Brown University Research FoundationImplanting devices for the focal release of neuroinhibitory compoundsUS5480598 *May 21, 1992Jan 2, 1996Brown Univ. Research FoundationProcess of and apparatus for making hollow fibersUS5487739 *Jun 2, 1995Jan 30, 1996Brown University Research FoundationImplantable therapy systems and methodsUS5498254 *Jan 13, 1995Mar 12, 1996Regents Of The University Of MinnesotaSmooth muscle chemical pacemakerUS5545223 *Mar 30, 1995Aug 13, 1996Baxter International, Inc.Ported tissue implant systems and methods of using sameUS5550050 *Apr 15, 1994Aug 27, 1996Cytotherapeutics, Inc.Method for implanting encapsulated cells in a hostUS5554148 *May 26, 1995Sep 10, 1996Brown University Research FoundationRenewable neural implant device and methodUS5569462 *Mar 31, 1995Oct 29, 1996Baxter International Inc.Methods for enhancing vascularization of implant devicesUS5591445 *Oct 10, 1995Jan 7, 1997Regents Of The University Of MinnesotaSmooth muscle chemical pacemakerUS5593440 *May 23, 1994Jan 14, 1997Baxter International Inc.Tissue implant systems and methods for sustaining viable high cell densities within a hostUS5618531 *Jul 13, 1993Apr 8, 1997New York UniversityMethod for increasing the viability of cells which are administered to the brain or spinal cordUS5639275 *May 25, 1995Jun 17, 1997Cytotherapeutics, Inc.Delivery of biologically active molecules using cells contained in biocompatible immunoisolatory capsulesUS5641749 *Nov 29, 1995Jun 24, 1997Amgen Inc.Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein productUS5641750 *Nov 29, 1995Jun 24, 1997Amgen Inc.Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein productUS5643773 *Apr 27, 1995Jul 1, 1997Brown University Research FoundationPreparation of elongated seamless capsules containing a coaxial rod and biological materialUS5653756 *Sep 2, 1994Aug 5, 1997Baxter International Inc.Closed porous chambers for implanting tissue in a hostUS5653975 *May 25, 1995Aug 5, 1997Cytotherapeutics, Inc.Compositions and methods for the delivery of biologically active molecules using cells contained in biocompatible capsulesUS5656481 *May 25, 1995Aug 12, 1997Cyto Therapeutics, Inc.Compositions and methods for the delivery of biologically active molecules using cells contained in biocompatible capsulesUS5676924 *Dec 17, 1993Oct 14, 1997Rhode Island HospitalIn vivo assay to determine cancer treatment effectivenessUS5676943 *May 25, 1995Oct 14, 1997Cytotherapeutics, Inc.Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsulesUS5681740 *Jun 5, 1995Oct 28, 1997Cytotherapeutics, Inc.Apparatus and method for storage and transporation of bioartificial organsUS5698413 *May 5, 1993Dec 16, 1997The United States Of America As Represented By The Department Of Health And Human ServicesMethod of evaluating chemotherapeutic agents in vivoUS5713888 *Jun 5, 1995Feb 3, 1998Baxter International, Inc.Tissue implant systemsUS5731284 *Sep 28, 1995Mar 24, 1998Amgen Inc.Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein productUS5733336 *Mar 30, 1995Mar 31, 1998Baxter International, Inc.Ported tissue implant systems and methods of using sameUS5741330 *Jun 7, 1995Apr 21, 1998Baxter International, Inc.Close vascularization implant materialUS5741778 *Mar 19, 1996Apr 21, 1998Amgen Inc.Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein productUS5750103 *Jun 2, 1995May 12, 1998The New York University Medical CenterMethod for transplanting cells into the brain and therapeutic uses thereforUS5753491 *Jun 6, 1995May 19, 1998Us HealthUse of neuro-derived fetal cell lines for transplantation therapyUS5762959 *May 28, 1993Jun 9, 1998Vivorx, Inc.Microencapsulation of cellsUS5773286 *May 24, 1995Jun 30, 1998Cytotherapeutics, Inc.Inner supported biocompatible cell capsulesUS5786216 *Nov 10, 1994Jul 28, 1998Cytotherapeutics, Inc.Inner-supported, biocompatible cell capsulesUS5788713 *Aug 21, 1997Aug 4, 1998University Of WashingtonMethod and apparatus for stereotactic implantationUS5792900 *Nov 9, 1994Aug 11, 1998The Trustees Of The University Of PennsylvaniaCompositions and methods for producing and using homogenous neuronal cell transplantsUS5798113 *May 24, 1995Aug 25, 1998Brown University Research FoundationImplantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic productsUS5800529 *Jun 7, 1995Sep 1, 1998Baxter International, Inc.Close vascularization implant materialUS5800828 *Jan 10, 1994Sep 1, 1998Brown University Research FoundationImplantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic productsUS5800829 *May 24, 1995Sep 1, 1998Brown University Research FoundationMethods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix coreUS5834001 *May 24, 1995Nov 10, 1998Brown University Research FoundationMethods for making immunoisolatory implantable vehicles with a biocompatiable jacket and a biocompatible matrix coreUS5837234 *Jun 7, 1995Nov 17, 1998Cytotherapeutics, Inc.Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membraneUS5855613 *Oct 13, 1995Jan 5, 1999Islet Sheet Medical, Inc.Retrievable bioartificial implants having dimensions allowing rapid diffusion of oxygen and rapid biological response to physiological changeUS5869077 *May 24, 1995Feb 9, 1999Brown University Research FoundationMethods for treating diabetes by delivering insulin from biocompatible cell-containing devicesUS5869463 *Jun 2, 1995Feb 9, 1999The United States Of America As Represented By The Department Of Health And Human ServicesUse of neuro-glial cell lines for transplantation therapyUS5871767 *May 24, 1995Feb 16, 1999Brown University Research FoundationMethods for treatment or prevention of neurodegenerative conditions using immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix coreUS5871985 *Aug 22, 1994Feb 16, 1999Brown University Research FoundationParticulate non cross-linked chitosan core matrices for encapsulated cellsUS5874099 *May 24, 1995Feb 23, 1999Brown University Research FoundationMethods for making immunoisolatary implantable vehicles with a biocompatible jacket and a biocompatible matrix coreUS5882354 *Jun 7, 1995Mar 16, 1999Baxter International Inc.Close vascularization implant materialUS5902745 *May 21, 1997May 11, 1999Gore Hybrid Technologies, Inc.Cell encapsulation deviceUS5908623 *May 25, 1995Jun 1, 1999Cytotherapeutics, Inc.Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsulesUS5932460 *Jun 6, 1995Aug 3, 1999Brown University Research FoundationMethod and apparatus for sealing implantable, membrane encapsulation devices containing living cellsUS5935795 *May 26, 1995Aug 10, 1999Amgen Inc.Glial cell line-derived neurotrophic factor antibodyUS5964804 *Jun 7, 1995Oct 12, 1999Baxter International Inc.Close vascularization implant materialUS5968502 *May 26, 1995Oct 19, 1999Transkaryotic Therapies, Inc.Protein production and protein deliveryUS5968905 *Aug 1, 1997Oct 19, 1999California Institute Of TechnologyStimulation of nerve growth and/or vitalityUS5973119 *Jun 5, 1998Oct 26, 1999Amgen Inc.Cyclin E genes and proteinsUS5980889 *Aug 5, 1997Nov 9, 1999Gore Hybrid Technologies, Inc.Cell encapsulating device containing a cell displacing core for maintaining cell viabilityUS5980927 *Jan 2, 1997Nov 9, 1999Medtronic, Inc.Method and apparatus for administering analgesics, and method for making same deviceUS5994127 *Nov 4, 1994Nov 30, 1999Transkaryotic Therapies, Inc.In vivo production and delivery of erythropoietin or insulinotropin for gene therapyUS6015572 *May 30, 1995Jan 18, 2000Amgen Inc.Implantable device containing GDNF secreting cells for treating nerve damage and methods of useUS6026316 *May 15, 1997Feb 15, 2000Regents Of The University Of MinnesotaMethod and apparatus for use with MR imagingUS6027721 *May 20, 1996Feb 22, 2000Cytotherapeutics, Inc.Device and method for encapsulated gene therapyUS6048524 *May 22, 1995Apr 11, 2000Transkaryotic Therapies, Inc.In vivo production and delivery of erythropoietin for gene therapyUS6048724 *May 22, 1995Apr 11, 2000Transkaryotic Therapies Inc.Method of producing clonal cell strains which express exogenous DNA encoding glucagon-like peptide 1US6048729 *Nov 4, 1994Apr 11, 2000Transkaryotic Therapies, Inc.In vivo protein production and delivery system for gene therapyUS6054142 *Aug 1, 1996Apr 25, 2000Cyto Therapeutics, Inc.Biocompatible devices with foam scaffoldsUS6054288 *May 18, 1995Apr 25, 2000Transkaryotic Therapies, Inc.In vivo protein production and delivery system for gene therapyUS6060048 *Jun 2, 1995May 9, 2000New York UniversityMethod for transplanting cells into the brain and therapeutic uses thereforUS6061587 *May 15, 1997May 9, 2000Regents Of The University Of MinnesotaMethod and apparatus for use with MR imagingUS6063630 *Apr 20, 1994May 16, 2000Transkaryotic Therapies, Inc.Targeted introduction of DNA into primary or secondary cells and their use for gene therapyUS6083523 *Sep 4, 1998Jul 4, 2000Brown University Research FoundationImplantable biocompatable immunoisolatory vehicle for delivery of selected therapeutic productsUS6093180 *Aug 18, 1997Jul 25, 2000Medtronic, Inc.Intraparenchymal infusion catheter systemUS6093802 *May 26, 1995Jul 25, 2000Amgen Inc.Glial cell line-derived neurotrophic factorUS6109269 *Apr 30, 1999Aug 29, 2000Medtronic, Inc.Method of treating addiction by brain infusionUS6110707 *Jan 17, 1997Aug 29, 2000Board Of Regents, The University Of Texas SystemRecombinant expression of proteins from secretory cell linesUS6121415 *Jul 24, 1997Sep 19, 2000Genentech, Inc.ErbB4 receptor-specific neuregolin related ligands and uses thereforUS6139578 *Feb 13, 1998Oct 31, 2000Etex CorporationPreparation of cell seeded ceramic compositionsUS6140089 *Feb 16, 1999Oct 31, 2000Brown University Research FoundationChitosan core matrix containing cells encapsulated in a thermoplastic semipermeable membraneUS6156305 *Jun 5, 1995Dec 5, 2000Baxter International Inc.Implanted tumor cells for the prevention and treatment of cancerUS6156728 *Oct 31, 1997Dec 5, 2000Genentech, Inc.Treatment of inner ear hair cellsUS6165225 *Aug 3, 1998Dec 26, 2000Islet Sheet Medical LlcRetrievable bioartificial implants having dimensions allowing rapid diffusion of oxygen and rapid biological response to physiological change, processes for their manufacture, and methods for their useUS6165753 *Dec 30, 1998Dec 26, 2000Amgen Inc.Cyclin E genes and proteinsUS6176242Apr 30, 1999Jan 23, 2001Medtronic IncMethod of treating manic depression by brain infusionUS6179826Oct 29, 1996Jan 30, 2001Brown University Research FoundationImplantable therapy systems and methodsUS6184200Sep 28, 1995Feb 6, 2001Amgen Inc.Truncated glial cell line-derived neurotrophic factorUS6194176Jan 17, 1997Feb 27, 2001Board Of Regents, The University Of Texas SystemRecombinant expression of proteins from secretory cell linesUS6200589Feb 27, 1998Mar 13, 2001The University Of AkronBiological implants of semipermeable amphiphilic membranesUS6214370Apr 9, 1999Apr 10, 2001Medtronic, Inc.Method and device for administering analgesicsUS6214622May 18, 1995Apr 10, 2001Transkaryotic Therapies, Inc.Targeted introduction of DNA into primary or secondary cells and their use for gene therapyUS6221376Sep 22, 1997Apr 24, 2001Amgen Inc.Glial cell line-derived neurotrophic factorUS6231879Jul 31, 1997May 15, 2001Neurotech S.A.Biocompatible devices with foam scaffoldsUS6252051Jul 30, 1998Jun 26, 2001Genentech, Inc.ErbB4 receptor-specific neuregulin related ligand antibodies and uses thereforUS6263237 *Feb 14, 2000Jul 17, 2001Medtronic, Inc.Techniques for treating anxiety disorders by brain stimulation and drug infusionUS6264941Jan 25, 1999Jul 24, 2001Neurotech S.A.Compositions for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsulesUS6264943Dec 10, 1999Jul 24, 2001New York UniversityMethod for transplanting cells into the brain and therapeutic uses thereforUS6270989Mar 17, 1995Aug 7, 2001Transkaryotic Therapies, Inc.Protein production and deliveryUS6272370Aug 7, 1998Aug 7, 2001The Regents Of University Of MinnesotaMR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imagingUS6277151Feb 13, 1998Aug 21, 2001Etex CorporationCartilage growth from cell seeded ceramic compositionsUS6291516Oct 14, 1999Sep 18, 2001Curis, Inc.Regulators of the hedgehog pathway, compositions and uses related theretoUS6303379Jul 16, 1999Oct 16, 2001Transkaryotic Therapies, Inc.Vivo protein production and delivery system for gene therapyUS6303749Jan 29, 1999Oct 16, 2001Amgen Inc.Agouti and agouti-related peptide analogsUS6313254Sep 19, 1997Nov 6, 2001Cardiac Crc Nominees Pty LtdPolysiloxane-containing polyurethane elastomeric compositionsUS6322804May 2, 2000Nov 27, 2001Neurotech S.A.Implantable biocompatible immunoisolatory vehicle for the delivery of selected therapeutic productsUS6344541Sep 25, 1998Feb 5, 2002Amgen Inc.DKR polypeptidesUS6355241Oct 19, 1999Mar 12, 2002Transkaryotic Therapies, Inc.In vivo production and delivery of erythropoietinUS6361771Apr 5, 2000Mar 26, 2002Neurotech S.A.ARPE-19 as a platform cell line for encapsulated cell-based deliveryUS6362319May 26, 1995Mar 26, 2002Amgen Inc.Glial cell line-derived neurotrophic factorUS6372244Aug 25, 2000Apr 16, 2002Islet Sheet Medical, Inc.Retrievable bioartificial implants having dimensions allowing rapid diffusion of oxygen and rapid biological response to physiological change, processes for their manufacture, and methods for their useUS6416510Oct 13, 1999Jul 9, 2002Biocardia, Inc.Drug delivery catheters that attach to tissue and methods for their useUS6426214Nov 8, 1999Jul 30, 2002Gore Enterprise Holdings, Inc.Cell encapsulating device containing a cell displacing core for maintaining cell viabilityUS6443941 *Jul 24, 2000Sep 3, 2002Endoluminal Therapeutics, Inc.Biodegradable polymeric endoluminal sealing process, apparatus and polymeric products for use thereinUS6455277Apr 14, 1997Sep 24, 2002Amgen Inc.Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptidesUS6463317May 19, 1998Oct 8, 2002Regents Of The University Of MinnesotaDevice and method for the endovascular treatment of aneurysmsUS6478776Apr 5, 2000Nov 12, 2002Biocardia, Inc.Implant delivery catheter system and methods for its useUS6531124Aug 16, 1999Mar 11, 2003Transkaryotic Therapies, Inc.In vivo production and delivery of insulinotropin for gene therapyUS6537241May 17, 1999Mar 25, 2003Twin Star Medical, Inc.System and method for site specific therapyUS6537542Apr 14, 2000Mar 25, 2003Transkaryotic Therapies, Inc.Targeted introduction of DNA into primary or secondary cells and their use for gene therapy and protein productionUS6544290Feb 13, 1998Apr 8, 2003Etex CorporationCell seeding of ceramic compositionsUS6547787Oct 13, 1999Apr 15, 2003Biocardia, Inc.Drug delivery catheters that attach to tissue and methods for their useUS6565844May 14, 1999May 20, 2003Transkaryotic Therapies, Inc.Protein production and protein deliveryUS6593290Nov 4, 1996Jul 15, 2003Genentech, Inc.Treatment of inner ear hair cellsUS6594880May 23, 2001Jul 22, 2003Medtronic, Inc.Intraparenchymal infusion catheter systemUS6613798Nov 28, 2000Sep 2, 2003Curis, Inc.Small organic molecule regulators of cell proliferationUS6627724Dec 13, 2000Sep 30, 2003Aortech Biomaterials Pty LtdPolysiloxane-containing polyurethane elastomeric compositionsUS6653279Aug 23, 2000Nov 25, 2003Genentech, Inc.Treatment of inner ear hair cellsUS6663913Dec 22, 1997Dec 16, 2003Scientec Research Pty. Ltd.Method of coating a bioactive substanceUS6670178Apr 19, 2000Dec 30, 2003Transkaryotic Therapies, Inc.In Vivo production and delivery of insulinotropin for gene therapyUS6683108Nov 28, 2000Jan 27, 2004Curis, Inc.Agonists of hedgehog signaling pathways and uses related theretoUS6686388May 29, 2001Feb 3, 2004Curis, Inc.Regulators of the hedgehog pathway, compositions and uses related theretoUS6692737Apr 13, 2000Feb 17, 2004Transkaryotic Therapies, Inc.In vivo protein production and delivery system for gene therapyUS6696290Mar 12, 1999Feb 24, 2004Genentech, Inc.ErbB2 and ErbB4 Chimeric Heteromultimeric AdhesinsUS6699272Dec 13, 2001Mar 2, 2004Endoluminal Therapeutics, Inc.Biodegradable polymeric endoluminal sealing process, apparatus and polymeric products for use thereinUS6758828Dec 10, 2001Jul 6, 2004Regents Of The University Of MinnesotaCatheter for cell delivery in tissueUS6773458 *Dec 12, 1994Aug 10, 2004Baxter International Inc.Angiogenic tissue implant systems and methodsUS6846676Jun 8, 1999Jan 25, 2005Transkaryotic Therapies, Inc.In Vivo production and delivery of erythropoietin or insulinotropin for gene therapyUS6908732Oct 15, 2001Jun 21, 2005President & Fellows Of Harvard CollegeCompounds and methods for regulating cell differentiationUS6916918Jun 5, 2001Jul 12, 2005Cell Genesys, Inc.Human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereofUS6927204Jun 9, 2003Aug 9, 2005Genentech, Inc.Treatment of inner ear hair cellsUS6943238Oct 4, 2002Sep 13, 2005Amgen, Inc.Antibodies to cyclin E2 proteinUS6960351Jul 21, 2003Nov 1, 2005Brown University Research FoundationImplantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic productsUS6971998Nov 12, 2002Dec 6, 2005Biocardia, Inc.Implant delivery catheter system and methods for its useUS6994856Jun 30, 1998Feb 7, 2006Genentech, Inc.ErbB4 receptor-specific neuregulin related ligands and uses thereforUS7048716Nov 24, 1999May 23, 2006Stanford UniversityMR-compatible devicesUS7069634Feb 24, 2000Jul 4, 2006Medtronic, Inc.Method for manufacturing a catheterUS7070557 *Mar 4, 2004Jul 4, 2006Marctec, LlcTissue graft material and method of makingUS7115257Apr 6, 2000Oct 3, 2006Neurotech S.A.ARPE-19 as a platform cell line for encapsulated cell-based deliveryUS7115653Sep 17, 2002Oct 3, 2006Curis, Inc.Small organic molecule regulators of cell proliferationUS7134437Mar 22, 2002Nov 14, 2006Bonutti Ip, LlcMethod for utilizing human tissueUS7138251May 30, 1997Nov 21, 2006Amgen Inc.Polynucleotides encoding a neurotrophic factor receptorUS7160716May 9, 2003Jan 9, 2007Vladimir KalinaDevice for inducing an immune response in cancer therapyUS7226758Sep 17, 1992Jun 5, 2007Amgen Inc.Nucleic acids encoding glial cell line-derived neurotrophic factor (GDNF)US7241283Apr 25, 2003Jul 10, 2007Ad-Tech Medical Instrument Corp.Method for intracranial catheter treatment of brain tissueUS7255686Oct 28, 2005Aug 14, 2007Ad-Tech Medical Instrument Corp.Catheter assembly for intracranial treatmentUS7313442Apr 29, 2005Dec 25, 2007Advanced Neuromodulation Systems, Inc.Method of treating mood disorders and/or anxiety disorders by brain stimulationUS7322954Oct 28, 2005Jan 29, 2008Ad-Tech Medical Instrument Corp.Catheter assembly for intracranial treatment using dual lumensUS7346395Jun 18, 2004Mar 18, 2008Advanced Neuromodulation Systems, Inc.Method of treating depression, mood disorders and anxiety disorders using neuromodulationUS7361333Sep 12, 2003Apr 22, 2008Latta Paul PPrevention of diabetes through induction of immunological toleranceUS7361334Apr 13, 2004Apr 22, 2008Latta Paul PMethod of treatment of diabetes through induction of immunological toleranceUS7364736Jun 25, 2002Apr 29, 2008Amgen Inc.Antibodies to OPGLUS7390781Jan 7, 2004Jun 24, 2008Amgen Inc.Methods of using truncated glial cell line-derived neurotrophic factorUS7396809Feb 10, 2000Jul 8, 2008Curis, Inc.Methods and reagents for treating glucose metabolic disordersUS7408047Sep 7, 1999Aug 5, 2008Amgen Inc.Fibroblast growth factor-like polypeptidesUS7410799Jul 7, 2004Aug 12, 2008Shire Human Genetic Therapies, Inc.In vivo production and delivery of erythropoietin or insulinotropin for gene therapyUS7435796Jan 27, 2000Oct 14, 2008Amgen Inc.Antibodies which bind B7RP1US7455963Jul 28, 2005Nov 25, 2008Amgen Inc.Antibodies to cyclin E2 proteinUS7459540Aug 23, 2000Dec 2, 2008Amgen Inc.Fibroblast growth factor-like polypeptidesUS7465292Oct 28, 2005Dec 16, 2008Ad-Tech Medical Instrument Corp.Catheter system for intracranial treatmentUS7468242Apr 29, 2004Dec 23, 2008Medgenics, Inc.Dermal micro organs, methods and apparatuses for producing and using the sameUS7579180Feb 28, 2007Aug 25, 2009Amgen Inc.Beta secretase polypeptidesUS7582465Feb 28, 2007Sep 1, 2009Amgen Inc.Beta secretase genesUS7611865May 26, 2004Nov 3, 2009Amgen Inc.Polynucleotides encoding truncated glial cell line-derived neurotrophic factorUS7616998Jul 9, 2004Nov 10, 2009Medtronic, Inc.Electrical stimulation of structures within the brainUS7653433Sep 1, 2006Jan 26, 2010Advanced Neuromodulation Systems, Inc.Method of treating depression, mood disorders and anxiety disorders using neuromodulationUS7659368Dec 22, 2003Feb 9, 2010Genentech, Inc.ErbB2 and ErbB3 chimeric heteromultimer adhesinsUS7662585Sep 17, 2004Feb 16, 2010Genentech, Inc.ErbB4 receptor-specific neuregulin related ligands and uses thereforUS7662924Nov 7, 2005Feb 16, 2010The Board Of Trustees Of The University Of IllinoisBeta chain-associated regulator of apoptosisUS7667008Apr 11, 2007Feb 23, 2010Amgen, Inc.Fibroblast growth factor-like polypeptides and variants thereofUS7671180Apr 11, 2007Mar 2, 2010Amgen, Inc.Fibroblast growth factor-like polypeptides and variants thereofUS7687057Dec 17, 2002Mar 30, 2010Yissum Research Development Company Of The Hebrew University Of JerusalemIn vitro micro-organs, and uses related theretoUS7695938Nov 13, 2008Apr 13, 2010Amgen Inc.Vectors and recombinant host cells comprising nucleic acid molecules encoding Fibroblast Growth Factor-like polypeptidesUS7696172Jun 27, 2008Apr 13, 2010Amgen Inc.Fibroblast growth factor-like polypeptidesUS7700558Jun 27, 2008Apr 20, 2010Amgen Inc.Methods for treating diabetes using fibroblast growth factor-like polypeptidesUS7704952Jun 27, 2008Apr 27, 2010Amgen Inc.Methods for treating diabetes using fibroblast growth factor-like polypeptidesUS7705195Jun 4, 2003Apr 27, 2010Genentech, Inc.Screening methodUS7708993Feb 21, 2006May 4, 2010Amgen Inc.Polypeptides involved in immune responseUS7713542May 18, 2005May 11, 2010Ada FoundationThree dimensional cell protector/pore architecture formation for bone and tissue constructsUS7718776Apr 7, 2003May 18, 2010Amgen Inc.Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitorsUS7723471Dec 12, 2005May 25, 2010Amylin Pharmaceuticals, Inc.Pancreatic polypeptide family motifs, polypeptides and methods comprising the sameUS7723478Aug 14, 2007May 25, 2010Amgen Inc.DKR polypeptidesUS7727283Mar 4, 2004Jun 1, 2010P Tech, Llc.Tissue stabilizing implant methodUS7727742Jun 27, 2008Jun 1, 2010Amgen Inc.Nucleic acid molecules encoding fibroblast growth factor-like polypeptidesUS7745216May 27, 2004Jun 29, 2010Curis, Inc.Methods and reagents for treating glucose metabolic disordersUS7807641Feb 6, 2007Oct 5, 2010Curis, Inc.Methods and reagents for treating glucose metabolic disordersUS7820195Dec 18, 2006Oct 26, 2010Neurotech Usa, Inc.Micronized device for the delivery of biologically active molecules and methods of use thereofUS7846453Jun 15, 2006Dec 7, 2010Genentech, Inc.Methods of stimulating ErbB4 receptor phosphorylationUS7879323Nov 13, 2008Feb 1, 2011Amgen Inc.Antibodies to fibroblast growth factor-like polypeptidesUS7884073Jun 26, 2006Feb 8, 2011Hanall Biopharma Co., Ltd.Modified growth hormoneUS7884078Feb 9, 2007Feb 8, 2011Massachusetts Institute Of TechnologyCPG15 compounds as insulin receptor and insulin-like growth factor receptor agonistsUS7887799Nov 13, 2008Feb 15, 2011Amgen Inc.Antibodies to fibroblast growth factor-like polypeptidesUS7896880Nov 15, 2001Mar 1, 2011P Tech, LlcApparatus and method for tissue removalUS7906625Jan 23, 2006Mar 15, 2011Amgen Inc.Humanized anti-amyloid antibodyUS7981418 *Mar 1, 2008Jul 19, 2011Genentech, Inc.Predicting response to a HER inhibitorUS7998128May 15, 2006Aug 16, 2011Therataxis, LLC.Active delivery and flow redirection: novel devices and method of delivery of materials to patientsUS7998930Nov 3, 2005Aug 16, 2011Hanall Biopharma Co., Ltd.Modified growth hormonesUS8027740Jul 5, 2002Sep 27, 2011Biocardia, Inc.Drug delivery catheters that attach to tissue and methods for their useUS8030275Mar 10, 2010Oct 4, 2011Amgen Inc.Methods for treating obesity using fibroblast growth factor-like polypeptidesUS8034770Jun 3, 2009Oct 11, 2011Amgen Inc.FGF21 polypeptides comprising two or more mutationsUS8039437Jun 30, 2009Oct 18, 2011The Trustees Of The University Of PennsylvaniaFn14/TRAIL fusion proteinsUS8044024Jun 1, 2010Oct 25, 2011Amgen Inc.Identifying modulators of fibroblast growth factor-like polypeptidesUS8048419Feb 1, 2007Nov 1, 2011Innovative Biotherapies, Inc.Extracorporeal cell-based therapeutic device and delivery systemUS8052970Jun 30, 2009Nov 8, 2011The Regents Of The University Of MichiganLysosomal phospholipase A2 (LPLA2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosisUS8053408Mar 10, 2010Nov 8, 2011Amgen Inc.Methods for treating obesity using fibroblast growth factor-like polypeptidesUS8088567Mar 30, 2006Jan 3, 2012Nsgene A/SHuman immortalised neural precursor cell lineUS8088568Oct 1, 2009Jan 3, 2012Medgentics, Inc.Dermal micro-organs, methods and apparatuses for producing and using the sameUS8119398Dec 30, 2005Feb 21, 2012Primegen Biotech LlcAdipose-derived stem cells for tissue regeneration and wound healingUS8129425Apr 27, 2006Mar 6, 2012Curis, Inc.Small organic molecule regulators of cell proliferationUS8142990Jul 2, 2008Mar 27, 2012Medgenics Inc.Dermal micro-organs, methods and apparatuses for producing and using the sameUS8147860Dec 6, 2005Apr 3, 2012Etex CorporationPorous calcium phosphate bone materialUS8188040May 4, 2010May 29, 2012Amgen Inc.FGF21 mutants and uses thereofUS8190264Jan 12, 2010May 29, 2012Advanced Neuromodulation Systems, Inc.Method of treating depression, mood disorders and anxiety disorders using neuromodulationUS8202701Oct 7, 2005Jun 19, 2012Georgia Tech Research CorporationMicroencapsulation of cells in hydrogels using electrostatic potentialsUS8211428Jul 5, 2007Jul 3, 2012Torrey Pines Institute For Molecular StudiesProtease screening methods and proteases identified therebyUS8216359Apr 14, 2005Jul 10, 2012Etex CorporationDelayed-setting calcium phosphate pastesUS8221781Apr 12, 2004Jul 17, 2012Etex CorporationOsteoinductive bone materialUS8222209Jan 25, 2011Jul 17, 2012Hanall Biopharma Co., Ltd.Modified growth hormones that exhibit increased protease resistance and pharmaceutical compositions thereofUS8226935Dec 16, 2009Jul 24, 2012Genentech, Inc.ErbB2 and ErbB3 chimeric heteromultimer receptorsUS8252743Nov 28, 2007Aug 28, 2012Hanall Biopharma Co., Ltd.Modified erythropoietin polypeptides and uses thereof for treatmentUS8273713Dec 14, 2001Sep 25, 2012Amylin Pharmaceuticals, LlcMethods of treating obesity using PYY[3-36]US8293463Jun 23, 2011Oct 23, 2012Medgenics Inc.Dermal micro-organs, methods and apparatuses for producing and using the sameUS8309083Apr 2, 2010Nov 13, 2012Amgen, Inc.Polypeptides involved in immune responseUS8324160Jun 16, 2010Dec 4, 2012Amgen Inc.Chimeric polypeptides and uses thereofUS8329467Apr 18, 2008Dec 11, 2012Fox Chase Cancer CenterCompositions and methods for altering pancreas or liver functionUS8329657Aug 11, 2011Dec 11, 2012The Trustees Of The University Of PennsylvaniaFn14/TRAIL fusion proteins and method of treating cancerUS8361963Dec 16, 2011Jan 29, 2013Amgen Inc.Uses of FGF21 polypeptides comprising two or more mutationsUS8367063May 18, 2010Feb 5, 2013Amgen, Inc.Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitorsUS8372952Dec 1, 2010Feb 12, 2013Amgen Inc.Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klothoUS8383388Jun 15, 2007Feb 26, 2013Catalyst Biosciences, Inc.Modified coagulation factor IX polypeptides and use thereof for treatmentUS8410051Aug 2, 2011Apr 2, 2013Amgen Inc.FGF21 mutants and uses thereofUS8414893Dec 19, 2008Apr 9, 2013Amgen Inc.Anti-amyloid antibodies and uses thereofUS8426361Dec 17, 2009Apr 23, 2013Amylin Pharmaceuticals, LlcPancreatic polypeptide family motifs, polypeptides and methods comprising the sameUS8454948Jan 10, 2012Jun 4, 2013Medgenics Medical Israel Ltd.Long lasting drug formulationsUS8454988Jan 23, 2008Jun 4, 2013Etex CorporationOsteoinductive bone materialUS8455629Jan 27, 2012Jun 4, 2013Amgen Inc.Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitorsUS8467878May 23, 2012Jun 18, 2013Advanced Neuromodulation Systems, Inc.Method of treating depression, mood disorders and anxiety disorders using neuromodulationUS8470317Sep 25, 2008Jun 25, 2013Amgen Inc.B7RP-1 antagonistsUS8501396Mar 14, 2012Aug 6, 2013Medgenics Medical Israel Ltd.Dermal micro-organs, methods and apparatuses for producing and using the sameUS8519103Apr 10, 2009Aug 27, 2013Catalyst Biosciences, Inc.Factor VII polypeptides that are modified and uses thereofUS8529550Dec 6, 2005Sep 10, 2013Biocardia, Inc.Implant delivery catheter system and methods for its useUS8530149Sep 27, 2011Sep 10, 2013Medgenics Medical Israel LtdDermal micro-organs, methods and apparatuses for producing and using the sameUS8538537Dec 8, 2008Sep 17, 2013Advanced Neuromodulations Systems, Inc.Systems and methods for providing targeted neural stimulation therapy to address neurological disorders, including neuropyschiatric and neuropyschological disordersUS8545858Apr 3, 2012Oct 1, 2013Etex CorporationPorous calcium phosphate bone materialUS8586024Jun 30, 2011Nov 19, 2013Medgenics Medical Israel Ltd.Long lasting drug formulationsUS8603969Feb 11, 2005Dec 10, 2013Amylin Pharmaceuticals, LlcPancreatic polypeptide family motifs and polypeptides comprising the sameUS8618053May 3, 2012Dec 31, 2013Amgen Inc.FGF21 mutants multimers and uses thereofUS8624010Nov 28, 2000Jan 7, 2014Steven K. YoshinagaNucleic acids encoding B7RP1US8629250Jan 30, 2008Jan 14, 2014Amgen Inc.Hepcidin, hepcidin antagonists and methods of useUS8642546Dec 15, 2011Feb 4, 2014Amgen Inc.FGF21 mutant fusion polypeptides and uses thereofUS8652469Jul 27, 2006Feb 18, 2014Novartis AgM-CSF-specific monoclonal antibody and uses thereofUS8663633Jul 2, 2012Mar 4, 2014Torrey Pines Institute For Molecular StudiesProtease screening methods and proteases identified therebyUS8685635Oct 22, 2012Apr 1, 2014Medgenics Medical Israel Ltd.Dermal micro-organs, methods and apparatuses for producing and using the sameUS8728536Mar 30, 2006May 20, 2014Etex CorporationChemotherapeutic composition using nanocrystalline calcium phosphate pasteUS8771291Nov 28, 2012Jul 8, 2014Medgenics Medical Israel Ltd.Dermal micro-organs, methods and apparatuses for producing and using the sameUS8771685Dec 22, 2010Jul 8, 2014F. Hoffmann-La Roche AgAnti-BV8 antibodies and uses thereofUS8778870Nov 3, 2011Jul 15, 2014Catalyst Biosciences, Inc.Modified factor IX polypeptides and uses thereofUS8795985Mar 22, 2012Aug 5, 2014Amgen Inc.FGF 21 polypeptides comprising two or more mutations and uses thereofUS8835385Mar 21, 2012Sep 16, 2014Amgen Inc.FGF21 polypeptides comprising two or more mutations and uses thereofUS8846868Apr 17, 2009Sep 30, 2014Fusion Antibodies LimitedAnti-AREG/HB-EGF antibodies and treatmentUS8852937Aug 20, 2007Oct 7, 2014Curis, Inc.Small organic molecule regulators of cell proliferationUS8877175Feb 26, 2013Nov 4, 2014Medgenics Medical Israel Ltd.Long lasting drug formulationsUS8906849Apr 8, 2013Dec 9, 2014Amylin Pharmaceuticals, LlcPancreatic polypeptide family motifs, polypeptides and methods comprising the sameUS8940302Oct 9, 2012Jan 27, 2015Genentech, Inc.Predicting response to a HER inhibitorUS9000132Jul 31, 2013Apr 7, 2015Diadexus, Inc.Lipoprotein-associated phospholipase A2 antibody compositions and methods of useUS9005614Nov 22, 2010Apr 14, 2015Novartis AgPRLR-specific antibody and uses thereofUS9029144Jun 16, 2009May 12, 2015Innovative Bio Therapies, Inc.Methods for enhanced propagation of cellsUS9101595Dec 2, 2012Aug 11, 2015Medgenics Medical Israel Ltd.Dermal micro-organs, methods and apparatuses for producing and using the sameUS9107896Feb 9, 2012Aug 18, 2015Medgenics Medical Israel Ltd.Dermal micro-organs, methods and apparatuses for producing and using the sameUS9121037 *May 29, 2014Sep 1, 2015Nsgene A/SCell lines and their use in encapsulated cell biodeliveryUS9127084Jun 15, 2011Sep 8, 2015Medgenics Medical Israel Ltd.Long lasting drug formulationsUS9144584Jun 8, 2009Sep 29, 2015Cell4Vet CorporationAdipose tissue-derived stem cells for veterinary useUS9145552Mar 15, 2013Sep 29, 2015Catalyst Biosciences, Inc.Modified factor X polypeptides and uses thereofUS9149427Nov 30, 2011Oct 6, 2015Neurotech Usa, Inc.Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereofUS9155749Sep 12, 2007Oct 13, 2015Medgenics Medical Israel Ltd.Long lasting drug formulationsUS9265577May 7, 2008Feb 23, 2016The Johns Hopkins UniversityMethods and systems for providing planning and dispensation of research and/or treatment for brain diseaseUS9265814Dec 18, 2006Feb 23, 2016Neurotech Usa, Inc.Micronized device for the delivery of biologically active molecules and methods of use thereofUS9266948May 29, 2014Feb 23, 2016Genentech, Inc.Anti-Bv8 antibodies and uses thereofUS9273106Dec 19, 2013Mar 1, 2016Amgen Inc.FGF mutants with reduced proteolysis and aggregationUS9279013Oct 8, 2009Mar 8, 2016Amgen Inc.FGF-21 mutants comprising polyethylene glycol and uses thereofUS9284378Dec 3, 2010Mar 15, 2016Shaw-Fen Sylvia HuHuman antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereofUS9290757May 18, 2012Mar 22, 2016Catalyst Biosciences, Inc.Protease screening methods and proteases identified therebyUS9309553Oct 13, 2011Apr 12, 2016The Regents Of The University Of MichiganLysosomal phospholipase A2 (LPLA2) activity as a therapeutic target for treating systemic lupus erythematosusUS9321838Apr 10, 2007Apr 26, 2016Fusion Antibodies LimitedTherapy targeting cathepsin SUS9328339May 1, 2014May 3, 2016Catalyst Biosciences, Inc.Modified factor IX polypeptides and uses thereofUS9364427May 15, 2006Jun 14, 2016Nsgene A/SImplantable therapy system for treating a living being with an active factorUS9388230Sep 28, 2011Jul 12, 2016Kahr Medical(2005) LtdCompositions and methods for treatment of hematological malignanciesUS9465029Apr 29, 2015Oct 11, 2016Glaxo Group LimitedMethods for detecting LP-PLA2 activity and inhibition of LP-PLA2 activityUS9468667Jun 30, 2013Oct 18, 2016Medgenics Medical Israel Ltd.Dermal micro-organs, methods and apparatuses for producing and using the sameUS9476037Jul 30, 2013Oct 25, 2016Catalyst Biosciences, Inc.Factor VII polypeptides that are modified and uses thereofUS9493530Jan 29, 2014Nov 15, 2016Amgen Inc.FGF21 mutants comprising a mutation at position 98, 171 and/or 180US9493577Feb 2, 2016Nov 15, 2016Amgen Inc.Human antigen binding proteins that bind β-klotho, FGF receptors and complexes thereofUS20020055755 *Nov 15, 2001May 9, 2002Bonutti Peter M.Apparatus and method for tissue removalUS20020099401 *Mar 22, 2002Jul 25, 2002Bonutti Petel M.Apparatus and method for tissue removalUS20020141985 *Dec 14, 2001Oct 3, 2002Amylin Parmaceuticals, Inc.Peptide YY and peptide YY agonists for treatment of metabolic disordersUS20020161178 *Oct 9, 2001Oct 31, 2002Amgen Inc.Novel DKR polypeptidesUS20020161200 *Apr 29, 2002Oct 31, 2002Genentech, Inc.ErbB4 receptor-specific neuregulin related ligands and uses thereforUS20020164321 *Jan 16, 2002Nov 7, 2002Gallina Damian J.Compositions and methods for treating retroviral infectionsUS20020177772 *Jul 5, 2002Nov 28, 2002Altman Peter A.Drug delivery catheters that attach to tissue and methods for their useUS20020197675 *Nov 13, 2001Dec 26, 2002Amgen Inc.Glial cell line-derived neurotrophic factorUS20030009147 *Sep 3, 2002Jan 9, 2003Bonutti Peter M.Biodegradable sac and method of using sameUS20030035301 *Jun 26, 2002Feb 20, 2003Allan GardinerMultiple wavelength illuminatorUS20030036166 *Aug 9, 2002Feb 20, 2003Genentech, Inc.ErbB4 receptor-specific neuregulin related ligands and uses thereforUS20030078370 *Oct 4, 2002Apr 24, 2003Amgen Inc.Antibodies to cyclin E2 proteinUS20030086914 *Jul 12, 2002May 8, 2003Yissum Research Development Company Of The Hebrew University Of JerusalemMethod and device for inducing biological processes by micro-organsUS20030103978 *Feb 22, 2001Jun 5, 2003Amgen Inc.Selective binding agents of osteoprotegerin binding proteinUS20030124565 *Jul 9, 2002Jul 3, 2003Garfinkel Leonard I.Efficient methods for assessing and validating ecandidate protein-based therapeutic molecules encoded by nucleic acid sequences of interestUS20030139457 *Sep 17, 2002Jul 24, 2003Curis, Inc.Small organic molecule regulators of cell proliferationUS20030147868 *Nov 18, 2002Aug 7, 2003Transkaryotic Therapies, Inc. A Delaware CorporationProtein production and protein deliveryUS20030152909 *Dec 17, 2002Aug 14, 2003Mitrani Eduardo N.In vitro micro-organs, and uses related theretoUS20030157074 *Dec 17, 2002Aug 21, 2003Mitrani Eduardo N.Vitro micro-organs, and uses related theretoUS20030167031 *Mar 24, 2003Sep 4, 2003Odland Rick MathewSystem and method for site specific therapyUS20030175876 *May 24, 2002Sep 18, 2003Amgen Inc.Glial cell line-derived neurotrophic factor receptorUS20030191499 *May 9, 2003Oct 9, 2003Vladimir KalinaApparatus for inducing an immune response in cancer therapyUS20040023313 *Apr 7, 2003Feb 5, 2004Boyle William JHuman anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitorsUS20040024419 *Jul 31, 2003Feb 5, 2004Endoluminal Therapeutics, Inc.Biodegradable polymeric endoluminal sealing process, apparatus and polymeric products for use thereinUS20040025194 *Feb 24, 2003Feb 5, 2004Board Of Trustees Of The University Of IllinoisBeta chain-associated regulator of apoptosisUS20040047848 *Sep 12, 2003Mar 11, 2004Latta Paul P.Induction of immunological toleranceUS20040127419 *Jan 7, 2004Jul 1, 2004AmgenMethods of using truncated glial cell line-derived neurotrophic factorUS20040127474 *Dec 12, 2003Jul 1, 2004Curis, Inc.Regulators of the hedgehog pathway, compositions and uses related theretoUS20040138417 *Dec 22, 2003Jul 15, 2004Genentech, Inc.Chimeric heteromultimer adhesinsUS20040147962 *May 9, 2003Jul 29, 2004Vladimir KalinaApparatus for inducing an immune response in cancer therapyUS20040169311 *Mar 4, 2004Sep 2, 2004Bonutti Peter M.Tissue graft material and method of makingUS20040172033 *Mar 4, 2004Sep 2, 2004Bonutti Peter M.Tissue stabilization device and methodUS20040175795 *Jan 14, 2004Sep 9, 2004Amgen Inc.Glial derived neurotrophic factorUS20040176291 *Sep 24, 2003Sep 9, 2004Elly NediviMethods and compositions for soluble CPG15US20040185083 *Jul 21, 2003Sep 23, 2004Dionne Keith E.Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic productsUS20040191227 *Apr 13, 2004Sep 30, 2004Latta Paul P.Induction of immunological toleranceUS20040214776 *May 25, 2004Oct 28, 2004Amgen Inc.Methods of using polynucleotides encoding truncated glial cell line-derived neurotrophic factorUS20040215162 *Apr 25, 2003Oct 28, 2004Ad-Tech Medical Instrument Corp.Intracranial catheter assembly for precise treatment of brain tissueUS20040228846 *May 27, 2004Nov 18, 2004Curis, Inc.Methods and reagents for treating glucose metabolic disordersUS20040235068 *Sep 4, 2002Nov 25, 2004Levinson Arthur D.Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disordersUS20040235714 *Jun 18, 2004Nov 25, 2004Amgen Inc.Neurotrophic factor receptorsUS20040241148 *Apr 29, 2004Dec 2, 2004Bellomo Stephen F.Dermal micro organs, methods and apparatuses for producing and using the sameUS20040254114 *May 26, 2004Dec 16, 2004Amgen Inc.Polynucleotides encoding truncated glial cell line-derived neurotrophic factorUS20050014796 *Dec 9, 2003Jan 20, 2005Curis, Inc.Mediators of hedgehog signaling pathways, compositions and uses related theretoUS20050049650 *Jul 9, 2004Mar 3, 2005Medtronic, Inc.Method for treating obsessive-compulsive disorder with electrical stimulation of the brain internal capsuleUS20050070578 *Sep 18, 2002Mar 31, 2005Baxter Anthony DavidSmall organic molecule regulators of cell proliferationUS20050084542 *Apr 12, 2004Apr 21, 2005Rosenberg Aron D.Osteoinductive bone materialUS20050136041 *Jul 7, 2004Jun 23, 2005Selden Richard F.In vivo production and delivery of erythropoietin or insulinotropin for gene therapyUS20050136467 *Jan 14, 2005Jun 23, 2005Genentech, Inc.ErbB4 receptor-specific neuregulin related ligands and uses thereforUS20050153330 *Nov 24, 2004Jul 14, 2005Amgen Inc.Novel DKR polypeptidesUS20050166274 *Jun 4, 2003Jul 28, 2005Dorothy FrenchCompositions and methods for the diagnosis and treatment of tumorUS20050187175 *Sep 30, 2004Aug 25, 2005Elly NediviMethods and compositions for CPG15-2US20050239061 *Mar 1, 2001Oct 27, 2005Marshall William SIdentification and use of effectors and allosteric molecules for the alteration of gene expressionUS20050239088 *May 14, 2004Oct 27, 2005Shepard H MIntron fusion proteins, and methods of identifying and using sameUS20060002930 *Apr 15, 2005Jan 5, 2006Genentech, Inc.Treatment of disordersUS20060020020 *Sep 19, 2005Jan 26, 2006Curis, Inc.Regulators of the hedgehog pathway, compositions and uses related theretoUS20060051351 *Oct 21, 2005Mar 9, 2006Genentech, Inc.ErbB4 receptor-specific neuregulin related ligands and uses thereforUS20060058743 *Oct 28, 2005Mar 16, 2006Putz David ADepth probe for intracranial treatmentUS20060064138 *Apr 29, 2005Mar 23, 2006Francisco VelascoMethod of treating mood disorders and/or anxiety disorders by brain stimulationUS20060079830 *Oct 28, 2005Apr 13, 2006Putz David ACatheter assembly for intracranial treatment using dual lumensUS20060079857 *Oct 28, 2005Apr 13, 2006Putz David ACatheter system for intracranial treatmentUS20060094653 *Feb 11, 2005May 4, 2006Levy Odile EPancreatic polypeptide family motifs and polypeptides comprising the sameUS20060106464 *Nov 23, 2005May 18, 2006Bonutti Peter MMethod for tissue graftingUS20060121505 *Nov 7, 2005Jun 8, 2006The Board Of Trustees Of The University Of IllinoisBeta chain-associated regulator of apoptosisUS20060122106 *Jun 13, 2003Jun 8, 2006Amylin Pharmaceuticals, IncPrevention and/or treatment of inflammatory bowel disease using pyy or agonists thereofUS20060127366 *Jul 13, 2003Jun 15, 2006Mitrani Eduardo NMethod and device for inducing biological processes by micro-organsUS20060129102 *Oct 28, 2005Jun 15, 2006Putz David ACatheter assembly for intracranial treatmentUS20060135747 *Dec 12, 2005Jun 22, 2006Levy Odile EPancreatic polypeptide family motifs, polypeptides and methods comprising the sameUS20060140944 *Feb 21, 2006Jun 29, 2006Amgen Inc.Novel polypeptides involved in immune responseUS20060147430 *Dec 30, 2005Jul 6, 2006Primegen Biotech LlcAdipose-derived stem cells for tissue regeneration and wound healingUS20060166325 *Jan 12, 2006Jul 27, 2006Amgen Inc.Glial cell line-derived neurotrophic factor receptorUS20060168672 *Sep 30, 2005Jul 27, 2006Amgen, Inc.B7-like molecules and uses thereofUS20060177446 *Nov 29, 2005Aug 10, 2006Genentech, Inc.Polypeptides that bind an anti-tissue factor antibody and uses thereofUS20060204505 *Mar 7, 2006Sep 14, 2006Sliwkowski Mark XMethods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)US20060212090 *Mar 1, 2006Sep 21, 2006Functional Neuroscience Inc.Method of treating cognitive disorders using neuromodulationUS20060212091 *Mar 1, 2006Sep 21, 2006Functional Neuroscience Inc.Method of treating depression, mood disorders and anxiety disorders using neuromodulationUS20060240121 *Mar 30, 2006Oct 26, 2006Lee Dosuk DChemotherapeutic composition using nanocrystalline calcium phosphate pasteUS20060247170 *Jun 26, 2006Nov 2, 2006Thierry GuyonModified growth hormonesUS20060251619 *May 4, 2006Nov 9, 2006Gilles BorrellyModified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptidesUS20060286102 *May 13, 2005Dec 21, 2006Pei JinCell surface receptor isoforms and methods of identifying and using the sameUS20060287385 *Apr 27, 2006Dec 21, 2006Curis, Inc.Small organic molecule regulators of cell proliferationUS20070005115 *Sep 1, 2006Jan 4, 2007Lozano Andres MMethod of treating depression, mood disorders and anxiety disorders using neuromodulationUS20070048822 *Jun 15, 2006Mar 1, 2007Genentech, Inc.ErbB4 receptor-specific neuregulin related ligands and uses thereforUS20070071734 *Oct 3, 2006Mar 29, 2007Weng TaoARPE-19 as platform cell line for encapsulated cell-based deliveryUS20070072294 *Dec 6, 2005Mar 29, 2007Doronin Sergey VUse of human stem cells and/or factors they produce to promote adult mammalian cardiac repair through cardiomyocyte cell divisionUS20070081994 *Sep 28, 2006Apr 12, 2007Genentech, Inc.Chimeric Heteromultimer AdhesinsUS20070087406 *May 4, 2006Apr 19, 2007Pei JinIsoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using sameUS20070093443 *Oct 20, 2006Apr 26, 2007Madison Edwin LModified proteases that inhibit complement activationUS20070143871 *Nov 6, 2006Jun 21, 2007Genentech, Inc.Non-human transgenic animal models for hepatocellular carcinomaUS20070161081 *Oct 31, 2006Jul 12, 2007Receptor Biologix, Inc.Hepatocyte growth factor intron fusion proteinsUS20070299010 *Feb 9, 2007Dec 27, 2007Elly NediviCPG15 and CPG15-2 compounds and inhibitors as insulin receptor and insulin-like growth factor receptor agonists and antagonistsUS20080003202 *Mar 27, 2007Jan 3, 2008Thierry GuyonModified interferon-beta (IFN-beta) polypeptidesUS20080026993 *Jun 26, 2006Jan 31, 2008Thierry GuyonModified growth hormonesUS20080028992 *Apr 14, 2005Feb 7, 2008Lee Dosuk DDelayed-Setting Calcium Phosphate PastesUS20080031962 *Oct 7, 2005Feb 7, 2008Boyan Barbara DMicroencapsulation of Cells in Hydrogels Using Electrostatic PotentialsUS20080038224 *Mar 27, 2007Feb 14, 2008Thierry GuyonModified interferon-beta (IFN-beta) polypeptidesUS20080057540 *Aug 14, 2007Mar 6, 2008Amgen Inc.Novel DKR polypeptidesUS20080071065 *Apr 11, 2007Mar 20, 2008Amgen, Inc.Fibroblast Growth Factor-Like PolypeptidesUS20080071066 *Apr 11, 2007Mar 20, 2008Amgen, Inc.Fibroblast Growth Factor-Like PolypeptidesUS20080090777 *Sep 12, 2007Apr 17, 2008Pearlman Andrew LLong lasting drug formulationsUS20080125388 *Feb 20, 2007May 29, 2008Elly NediviMethods and compositions for CPG15-2US20080152651 *Oct 24, 2007Jun 26, 2008Amgen Inc.Novel polypeptides involved in immune responseUS20080188406 *Feb 6, 2007Aug 7, 2008Curis, Inc.Methods and reagents for treating glucose metabolic disordersUS20080188946 *Jan 23, 2008Aug 7, 2008Etex CorporationOsteoinductive bone materialUS20080207740 *Aug 20, 2007Aug 28, 2008Curis, Inc.Small organic molecule regulators of cell proliferationUS20080213277 *Jan 30, 2008Sep 4, 2008Amgen Inc.Hepcidin, hepcidin antagonists and methods of useUS20080227745 *Feb 7, 2008Sep 18, 2008Massachusetts Institute Of TechnologyMethods and compositions for soluble CPG15US20080233118 *Jul 27, 2006Sep 25, 2008Novartis AgUses Of Antibody To M-CsfUS20080286250 *Oct 27, 2006Nov 20, 2008Jens TornoeImplantable Biocompatible Immunoisolatory Vehicle for Delivery of GdnfUS20080286323 *Jan 18, 2005Nov 20, 2008Nsgene A/SHuman Therapeutic Cells Secreting Nerve Growth FactorUS20080292639 *Jan 23, 2006Nov 27, 2008Amgen Inc.Humanized Anti-Amyloid AntibodyUS20090017498 *Jun 27, 2008Jan 15, 2009Amgen, Inc.Fibroblast Growth Factor-Like PolypeptidesUS20090018076 *Jun 27, 2008Jan 15, 2009Amgen, Inc.Fibroblast Growth Factor-Like PolypeptidesUS20090018077 *Jun 27, 2008Jan 15, 2009Amgen, Inc.Fibroblast Growth Factor-Like PolypeptidesUS20090081296 *Aug 15, 2008Mar 26, 2009Humes H DavidExtracorporeal cell-based therapeutic device and delivery systemUS20090082717 *Jul 2, 2008Mar 26, 2009Bellomo Stephen FDermal micro-organs, methods and apparatuses for producing and using the sameUS20090118182 *Jun 27, 2008May 7, 2009Amgen, Inc.Fibroblast Growth Factor-Like PolypeptidesUS20090123452 *Jul 5, 2007May 14, 2009Madison Edwin LProtease screening methods and proteases identified therebyUS20090136552 *Aug 1, 2005May 28, 2009Mette GronborgGrowth factors nsg28, nsg30, and nsg32US20090148885 *Nov 13, 2008Jun 11, 2009Amgen, Inc.Fibroblast Growth Factor-Like PolypeptidesUS20090149898 *Dec 8, 2008Jun 11, 2009Northstar Neuroscience, Inc.Systems and Methods for Providing Targeted Neural Stimulation Therapy to Address Neurological Disorders, Including Neuropyschiatric and Neuropyschological DisordersUS20090170769 *Oct 29, 2008Jul 2, 2009Pei JinCell surface receptor isoforms and methods of identifying and using the sameUS20090196854 *Feb 4, 2008Aug 6, 2009Kytos Biosystems S.A.Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based deliveryUS20090208504 *Sep 25, 2008Aug 20, 2009Amgen Inc.Polypeptides involved in immune responseUS20090209831 *Jan 15, 2009Aug 20, 2009Nexgen Medical Systems, IncorporatedImaging methods for visualizing implanted living cellsUS20090214474 *Apr 30, 2009Aug 27, 2009Barbara Brooke JenningsCompounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal developmentUS20090227978 *May 15, 2006Sep 10, 2009Wahlberg Lars UImplantable Therapy System for Treating a Living Being With an Active FactorUS20090269319 *Jul 8, 2009Oct 29, 2009Neurotech Usa, Inc.ARPE-19 as a Platform Cell Line for Encapsulated Cell-Based DeliveryUS20090269360 *Apr 10, 2007Oct 29, 2009Fusion Antibodies LimitedTherapyUS20090269389 *Jul 7, 2009Oct 29, 2009Neurotech Usa, Inc.ARPE-19 as a Platform Cell Line for Encapsulated Cell-Based DeliveryUS20090291890 *Apr 10, 2009Nov 26, 2009Madison Edwin LFactor VII polypeptides that are modified and uses thereofUS20090324575 *Jun 30, 2009Dec 31, 2009The Regents Of The University Of MichiganLysosomal phospholipase a2 (lpla2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosisUS20090324599 *Nov 13, 2008Dec 31, 2009Amgen Inc.Fibroblast Growth Factor-Like PolypeptidesUS20100028349 *Nov 13, 2008Feb 4, 2010Amgen Inc.Fibroblast Growth Factor-Like PolypeptidesUS20100030102 *May 14, 2007Feb 4, 2010David PostonActive Delivery and Flow Redirections: Novel Devices and Method of Delivery of Materials to PatientsUS20100048478 *Jun 30, 2009Feb 25, 2010Tykocinski Mark LFn14/trail fusion proteinsUS20100086525 *Apr 18, 2008Apr 8, 2010Zaret Kenneth SCompositions and Methods for Altering Pancreas or Liver FunctionUS20100086551 *Oct 12, 2007Apr 8, 2010Fusion Antibodies LimitedAntibody and uses thereofUS20100092464 *Jul 27, 2006Apr 15, 2010Novartis AgM-CSF-Specific Monoclonal Antibody and Uses ThereofUS20100099619 *Dec 17, 2009Apr 22, 2010Amylin Pharmaceuticals, Inc.Pancreatic polypeptide family motifs, polypeptides and methods comprising the sameUS20100104554 *Mar 2, 2007Apr 29, 2010Fusion Antibodies Limited, a Corporation of Great BritianPeptide and uses thereofUS20100111965 *Oct 11, 2007May 6, 2010Fusion Antibodies LimitedCombination therapyUS20100114193 *Jan 12, 2010May 6, 2010Advanced Neuromodulation Systems, Inc.Method of treating depression, mood disorders and anxiety disorders using neuromodulationUS20100129351 *Apr 18, 2008May 27, 2010Zaret Kenneth SCompositions and Methods for Altering Pancreas or Liver FunctionUS20100135957 *Dec 16, 2009Jun 3, 2010Vincent Danial FitzpatrickChimeric Heteromultimer AdhesinsUS20100136687 *Jun 16, 2009Jun 3, 2010Westover Angela JMethods for Enhanced Propagation of CellsUS20100143314 *Jun 24, 2008Jun 10, 2010Shire Human Genetic Therapies, Inc.In Vivo Production and Delivery of Erythropoietin or Insulinotropin for Gene TherapyUS20100158903 *Sep 16, 2009Jun 24, 2010Craig SmithMethods for treating progressive multiple sclerosisUS20100209435 *Feb 15, 2010Aug 19, 2010Amgen Inc.Human Anti-OPGL Neutralizing Antibodies As Selective OPGL Pathway InhibitorsUS20100226921 *Mar 10, 2010Sep 9, 2010Amgen Inc.Methods for treating obesity using Fibroblast Growth Factor-Like PolypeptidesUS20100233169 *Mar 10, 2010Sep 16, 2010Amgen Inc.Methods for treating obesity using fibroblast growth factor-Like polypeptidesUS20100247605 *May 10, 2010Sep 30, 2010American Dental Association FoundationThree Dimensional Cell Protector/Pore Architecture Formation for Bone and Tissue ConstructsUS20100260816 *Jun 25, 2010Oct 14, 2010Latta Paul PInduction of immunological toleranceUS20100272780 *Apr 21, 2010Oct 28, 2010Vincent LingCELL LINES THAT PRODUCE PROSTAGLANDIN F2 ALPHA (PGF2a) AND USES THEREOFUS20100285131 *May 4, 2010Nov 11, 2010Amgen Inc.Fgf21 mutants and uses thereofUS20100310566 *Jun 1, 2010Dec 9, 2010Amgen Inc.Fibroblast Growth Factor-Like PolypeptidesUS20100323954 *Jun 16, 2010Dec 23, 2010Amgen Inc.Chimeric polypeptides and uses thereofUS20100330050 *May 17, 2010Dec 30, 2010Doronin Sergey VUse of human stem cells and/or factors they produce to promote adult mammalian cardiac repair through cardiomyocyte cell divisionUS20110003302 *Jun 1, 2010Jan 6, 2011Amgen Inc.Fibroblast Growth Factor-Like PolypeptidesUS20110059068 *Apr 2, 2010Mar 10, 2011Amgen Inc.Polypeptides involved in immune responseUS20110111008 *Oct 6, 2010May 12, 2011Weng TaoUse of PEDF in an Encapsulated Cell-Based Delivery SystemUS20110135657 *Dec 3, 2010Jun 9, 2011Amgen Inc.Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereofUS20110150760 *Nov 22, 2010Jun 23, 2011Novartis AgPRLR-Specific Antibody and Uses ThereofUS20110150886 *Apr 17, 2009Jun 23, 2011Fusion Antibodies LimitedAnti-areg/hb-egf antibodies and treatmentUS20110150901 *Dec 1, 2010Jun 23, 2011Amgen Inc.Binding proteins that bind to human fgfr1c, human beta-klotho and both human fgfr1c and human beta-klothoUS20110182983 *Mar 30, 2006Jul 28, 2011Bengt JuliussonHuman immortalised neural precursor cell lineUS20110236457 *Dec 18, 2006Sep 29, 2011Konrad KauperMicronized Device for the Delivery of Biologically Active Molecules and Methods of Use ThereofUS20140377341 *May 29, 2014Dec 25, 2014Nsgene A/SCell lines and their use in encapsulated cell biodeliveryUS20150144552 *Feb 4, 2015May 28, 2015Corning IncorporatedImmobilized multi-layer artificial membrane for permeability measurements (pampa)CN105142570A *Apr 24, 2013Dec 9, 2015雀巢产品技术援助有限公司Encapsulation deviceEP0901796A2 *Sep 2, 1998Mar 17, 1999Circe Biomedical, Inc.Encapsulation deviceEP0906764A2 *Oct 2, 1998Apr 7, 1999JOHNSON & JOHNSON MEDICAL, INC.Biopolymer sponge tubesEP1486182A2 *Jun 4, 1996Dec 15, 2004Nephros Therapeutics, Inc.A device for delivering a preselected molecule into the systemic circulationEP1639972A1Jul 22, 2002Mar 29, 2006Anecova SAIntrauterine device, method of making such a device and method for putting active elements within the uterine cavityEP1978090A1Aug 9, 2001Oct 8, 2008ES Cell International Pte Ltd.Pancreatic progenitor cellsEP1997494A2Apr 22, 2003Dec 3, 2008The John Hopkins UniversityModulators of hedgehog signaling pathways, compositions and uses related theretoEP2002846A2Dec 8, 1997Dec 17, 2008Amgen Inc.Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseasesEP2016951A1Mar 10, 1999Jan 21, 2009Genentech, Inc.Polypeptides homologous to VEGF and BMP1EP2042596A1Nov 28, 2001Apr 1, 2009Amgen Inc.Polypeptides involved in immune responseEP2042597A1Jun 20, 2001Apr 1, 2009Genentech, Inc.Compositions and methods for the diagnosis and treatment of disorders involving angiogenesisEP2050763A2Mar 9, 2006Apr 22, 2009Genentech, Inc.Methods and compositions for modulating vascular integrityEP2052742A1Jun 14, 2001Apr 29, 2009Biogen Idec Inc.Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combinationEP2058329A1Jun 10, 2004May 13, 2009NsGene A/SImproved secretion of neublastinEP2062916A2Apr 6, 2004May 27, 2009Genentech, Inc.Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitorEP2075253A1Jun 20, 2001Jul 1, 2009Genentech, Inc.Compositions and methds for the diagnosis and treatment of disorders involving angiogensisEP2075254A1Mar 30, 2005Jul 1, 2009NsGene A/STherapeutic use of a growth factor, NsG33EP2077276A1Jun 20, 2001Jul 8, 2009Genentech, Inc.Compositions and methods for the diagnosis and treatment of disorders involving angiogensisEP2077279A1Jun 28, 2001Jul 8, 2009Amgen Inc.Thymic stromal lymphopoietin receptor molecules and uses thereofEP2083018A2Apr 16, 2004Jul 29, 2009Genentech, Inc.Compositions and methods relating to STOP-1EP2105449A2Feb 23, 2001Sep 30, 2009Amgen Inc.Antagonistic selective binding agents of osteoprotegerin binding proteinEP2112167A2Jun 23, 2000Oct 28, 2009Genentech, Inc.Humanized ANTI-ERBB2 antibodies and treatment with ANTI-ERBB2 antibodiesEP2130920A2Mar 28, 2001Dec 9, 2009Amgen, IncBeta-like glycoprotein hormone polypeptide and heterodimerEP2168980A1Jun 20, 2001Mar 31, 2010Genentech, Inc.Compositions and methods for the diagnosis and treatment of disorders involving angiogensisEP2189475A2Sep 5, 2000May 26, 2010Amgen Inc.Fibroblast growth factor-like polypeptidesEP2210617A1Oct 20, 2004Jul 28, 2010NsGene A/SMammalian cells secreting Neurturin and their therapeutic useEP2230517A1Jan 9, 2006Sep 22, 2010Diadexus, Inc.OVR110 antibody compositions and methods of useEP2241574A1Nov 4, 2005Oct 20, 2010HanAll Biopharma Co., Ltd.Modified growth hormonesEP2246363A1Nov 17, 2003Nov 3, 2010Novartis Vaccines and Diagnostics, Inc.Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasisEP2258722A2Sep 5, 2000Dec 8, 2010Amgen, IncAntibodies to fibroblast growth factor-like (FGF-like) polypeptidesEP2261254A2Dec 19, 2008Dec 15, 2010Amgen, IncAnti-amyloid antibodies and uses thereofEP2263691A1Jul 11, 2003Dec 22, 2010Genentech, Inc.Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)EP2274978A1Sep 9, 2004Jan 19, 2011Tercica, Inc.Methods for treatment of insulin-like growth factor-I(IGF-I) deficiencyEP2275549A1Jun 20, 2001Jan 19, 2011Genentech, Inc.Compositions and methods for the diagnosis and treatment of disorders involving angiogenesisEP2284189A2Sep 5, 2000Feb 16, 2011Amgen, IncNucleic acid molecules encoding fibroblast growth factor-like (FGF-like) polypeptidesEP2287192A1Nov 17, 2003Feb 23, 2011Novartis Vaccines and Diagnostics, Inc.Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasisEP2289911A2Mar 30, 2005Mar 2, 2011NsGene A/STherapeutic use of a growth factor, NsG33EP2301536A1Oct 13, 2005Mar 30, 2011PTC Therapeutics, Inc.Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseasesEP2301538A1Oct 13, 2005Mar 30, 2011PTC Therapeutics, Inc.Compounds for nonsense suppression, and methods for their useEP2305715A2Feb 23, 2001Apr 6, 2011Amgen, IncMonoclonal antibody to osteoprotegerin binding proteinEP2311455A1Oct 13, 2005Apr 20, 2011PTC Therapeutics, Inc.Compounds for nonsense suppression, and methods for their useEP2311873A1Jan 6, 2005Apr 20, 2011Novartis Vaccines and Diagnostics, Inc.M-CSF-specific monoclonal antibody and uses thereofEP2314318A1Jan 31, 2002Apr 27, 2011Biogen Idec Inc.CD80 antibody for use in combination with chemotherapeutics to treat B cell malignanciesEP2316452A1Oct 13, 2005May 4, 2011PTC Therapeutics, Inc.Pyrrol derivatives, uses thereofEP2316859A1Apr 10, 2006May 4, 2011Fusion Antibodies LimitedCathepsin S antibodyEP2319526A1Jun 17, 2005May 11, 2011Thrasos Therapeutics, Inc.Tdf-related compounds and analogs thereofEP2330197A2Feb 23, 2001Jun 8, 2011Amgen, IncAntagonistic selective binding agents of osteoprotegerin binding proteinEP2332976A1Jan 27, 2000Jun 15, 2011Amgen, IncNovel polypeptides involved in immune responseEP2332978A1Jan 27, 2000Jun 15, 2011Amgen, IncNovel polypeptides involved in immune responseEP2363129A1Oct 13, 2005Sep 7, 2011PTC Therapeutics, Inc.Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseasesEP2377401A1Apr 29, 2004Oct 19, 2011Medgenics, Inc.A genetically modified dermal micro-organ expressing erythropoietinEP2377402A1Apr 29, 2004Oct 19, 2011Medgenics, Inc.A genetically modified dermal micro-organ expressing interferonEP2377403A1Apr 29, 2004Oct 19, 2011Medgenics, Inc.A genetically modified dermal micro-organ expressing factor VIIIEP2377404A1Apr 29, 2004Oct 19, 2011Medgenics, Inc.A dermal micro-organ which is an explant of living tissueEP2382982A2Aug 22, 2002Nov 2, 2011Neuren Pharmaceuticals LimitedNeural regeneration peptide and methods for their use in treatment of brain damageEP2389946A1Mar 22, 2007Nov 30, 2011Novartis AGAnti-tumor cell antigen antibody therapeuticsEP2389947A1Mar 22, 2007Nov 30, 2011Novartis AGAnti-tumor cell antigen antibody therapeuticsEP2389948A1Mar 22, 2007Nov 30, 2011Novartis AGAnti-tumor cell antigen antibody therapeuticsEP2389949A1Mar 22, 2007Nov 30, 2011Novartis AGAnti-tumor cell antigen antibody therapeuticsEP2389950A1Mar 22, 2007Nov 30, 2011Novartis AGAnti-tumor cell antigen antibody therapeuticsEP2389951A1Mar 22, 2007Nov 30, 2011Novartis AGAnti-tumor cell antigen antibody therapeuticsEP2399605A1Feb 21, 2006Dec 28, 2011Genentech, Inc.Extending time to disease progression or survival in cancer patientsEP2402323A2Oct 13, 2005Jan 4, 2012PTC Therapeutics, Inc.Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseasesEP2402437A2Jul 5, 2007Jan 4, 2012Catalyst Biosciences, Inc.Protease screening methods and proteases identified therebyEP2402438A2Jul 5, 2007Jan 4, 2012Catalyst Biosciences, Inc.Protease screening methods and proteases identified therebyEP2423231A2Aug 17, 2007Feb 29, 2012Novartis AGPRLR-specific antibody and uses thereofEP2423305A1Jun 15, 2007Feb 29, 2012Catalyst Biosciences, Inc.Modified coagulation factor IX polypeptides and use thereof for treatmentEP2423306A1Jun 15, 2007Feb 29, 2012Catalyst Biosciences, Inc.Modified coagulation factor IX polypeptides and use thereof for treatmentEP2423307A1Jun 15, 2007Feb 29, 2012Catalyst Biosciences, Inc.Modified coagulation factor IV polypeptides and use thereof for treatmentEP2428218A1Oct 20, 2006Mar 14, 2012Catalyst Biosciences, Inc.Modified proteases that inhibit complement activationEP2430923A1Jun 5, 2003Mar 21, 2012Genentech, Inc.Compositions and methods for liver growth and liver protectionEP2433642A2Oct 20, 2006Mar 28, 2012Catalyst Biosciences, Inc.Modified proteases that inhibit complement activationEP2446898A1Sep 30, 2010May 2, 2012Laboratorios Del. Dr. Esteve, S.A.Use of growth hormone to enhance the immune response in immunosuppressed patientsEP2460827A1Jun 30, 2009Jun 6, 2012The Trustees Of The University Of PennsylvaniaFusion proteins comprising Fn14 and an inhibitory proteinEP2460875A1Mar 29, 2006Jun 6, 2012Stemnion, Inc.Amnion-derived cell compositions, methods of making and uses thereofEP2474557A2Jul 15, 2008Jul 11, 2012Genentech, Inc.Anti-CD79b antibodies and immunoconjugates and methods of useEP2476700A1Nov 4, 2005Jul 18, 2012HanAll Biopharma Co., Ltd.Modified growth hormonesEP2481797A1Apr 11, 2008Aug 1, 2012Catalyst Biosciences, Inc.Modified factor VII polypeptides and uses thereofEP2494988A1Dec 6, 2007Sep 5, 2012Novartis AGAntagonist antibodies against EPHB3EP2502937A2Jul 15, 2008Sep 26, 2012Genentech, Inc.Anti-CD 79b Antibodies And Immunoconjugates And Methods Of UseEP2551281A1Oct 24, 2008Jan 30, 2013Nevalaita, LinaSplice variants of GDNF and uses thereofEP2614839A2Jan 22, 2007Jul 17, 2013Genentech, Inc.Method for using BOC/CDO to modulate hedgehog signalingEP2641618A2Jul 15, 2008Sep 25, 2013Genentech, Inc.Humanized anti-CD79B antibodies and immunoconjugates and methods of useEP2657253A2Jan 14, 2009Oct 30, 2013Genentech, Inc.Anti-CD79b antibodies and immunoconjugates and methods of useEP2679678A1Apr 10, 2009Jan 1, 2014Catalyst Biosciences, Inc.Factor VII polypeptides that are modified and uses thereofEP2687596A2Apr 10, 2009Jan 22, 2014Catalyst Biosciences, Inc.Factor VII polypeptides that are modified and uses thereofEP2789342A1Jun 17, 2005Oct 15, 2014Thrasos Innovation, Inc.TDF-related compounds and analogs thereofEP2792747A1Jun 20, 2001Oct 22, 2014Genentech, Inc.Compositions and methods for the diagnosis and treatment of disorders involving angiogenesisEP2796465A1Jan 27, 2000Oct 29, 2014Amgen, IncPolypeptides involved in immune responseEP2801826A1Jul 18, 2011Nov 12, 2014F. Hoffmann-La Roche AGMethod to identify a patient with an increased likelihood of responding to an anti-cancer therapyEP2824457A1Jul 18, 2011Jan 14, 2015F. Hoffmann-La Roche AGMethod to identify a patient with an increased likelihood of responding to an anti-cancer therapyEP2848939A1Jul 18, 2011Mar 18, 2015F. Hoffmann-La Roche AGMethod to identify a patient with an increased likelihood of responding to an anti-cancer therapyEP2848940A1Jul 18, 2011Mar 18, 2015F. Hoffmann-La Roche AGMethod to identify a patient with an increased likelihood of responding to an anti-cancer therapyEP2857516A1Mar 20, 2001Apr 8, 2015Genentech, Inc.Multivalent antibodies and uses thereforEP2866032A1Jul 18, 2011Apr 29, 2015F. Hoffmann-La Roche AGMethod to identify a patient with an increased likelihood of responding to an anti-cancer therapyEP2899541A1Feb 29, 2008Jul 29, 2015Genentech, Inc.Predicting response to a HER dimerisation inhbitor based on low HER3 expressionEP2936984A1Apr 29, 2004Oct 28, 2015Medgenics, Inc.Apparatus and method for harvesting a dermal micro-organEP2939674A1Oct 13, 2005Nov 4, 2015PTC Therapeutics, Inc.Compounds for nonsense suppression, and methods for their useEP2962697A1Nov 27, 2007Jan 6, 2016diaDexus, Inc.Ovr110 antibody compositions and methods of useEP3002297A2Nov 29, 2010Apr 6, 2016F. Hoffmann-La Roche AGAntibodies for treating and diagnosing tumors expressing slc34a2 (tat211)EP3018144A1Aug 17, 2007May 11, 2016XOMA Technology Ltd.Prlr-specific antibody and uses thereofEP3034607A1Jul 5, 2007Jun 22, 2016Catalyst Biosciences, Inc.Protease screening methods and proteases identified therebyEP3056511A2Jun 21, 2006Aug 17, 2016Xoma (Us) LlcIl-1beta binding antibodies and fragments thereofEP3067053A1Oct 13, 2005Sep 14, 2016PTC Therapeutics, Inc.Compounds for nonsense suppression, and methods for their useWO1991010425A1 *Jan 8, 1991Jul 25, 1991Brown University Research FoundationCell capsule extrusion systemsWO1992006702A1 *Oct 9, 1991Apr 30, 1992New York UniversityA method for transplanting cells into the brain and therapeutic uses thereforWO1993000063A1 *Jun 25, 1992Jan 7, 1993Brown University Research FoundationCapsule extrusion systemsWO1993023431A1 *May 11, 1993Nov 25, 1993Baylor College Of MedicineMutated steroid hormone receptors, methods for their use and molecular switch for gene therapyWO1994007999A1 *Sep 22, 1993Apr 14, 1994Brown University Research FoundationChitosan matrices for encapsulated cellsWO1994013269A1 *Dec 8, 1993Jun 23, 1994Regents Of The University Of MinnesotaSmooth muscle chemical pacemakerWO1995006486A1 *Sep 2, 1994Mar 9, 1995Government Of The United States Of America, Secretary Department Of Health And Human ServicesTreatment of human tumors by genetic transformation of human tumor cellsWO1995012982A1 *Nov 9, 1994May 18, 1995The Trustees Of The University Of PennsylvaniaCompositions and methods for producing and using homogeneous neuronal cell transplantsWO1998050525A1 *May 6, 1998Nov 12, 1998Neuralstem BiopharmaceuticalsEmbryonic and adult cns stem cellsWO1999049807A2Jan 9, 1998Oct 7, 1999Yissum Research And Development Company Of The Hebrew University Of JerusalemA device and method for performing a biological modification of a fluidWO2001068705A2Mar 16, 2001Sep 20, 2001Amgen Inc.Il-17 receptor like molecules and uses thereofWO2004096124A2Apr 1, 2003Nov 11, 2004Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorWO2004101756A2May 10, 2004Nov 25, 2004Diadexus, Inc.Ovr110 antibody compositions and methods of useWO2004108760A2Jun 10, 2004Dec 16, 2004Nsgene A/SImproved secretion of neublastinWO2005014022A1Jul 15, 2004Feb 17, 2005Develogen AktiengesellschaftUse of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndromeWO2005017529A1Jun 24, 2004Feb 24, 2005Genentech, Inc.Assay for human anti cd20 antibodies and uses thereforWO2006074418A2Jan 9, 2006Jul 13, 2006Diadexus, Inc.Ovr110 antibody compositions and methods of useWO2006117212A2May 4, 2006Nov 9, 2006Develogen AktiengesellschaftUse of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disordersWO2007068803A1Dec 14, 2006Jun 21, 2007Licentia LtdNovel neurotrophic factor protein and uses thereofWO2007126455A2Jan 22, 2007Nov 8, 2007Genentech, Inc.Method for using boc/cdo to modulate hedgehog signalingWO2007131133A2May 3, 2007Nov 15, 2007Genentech, Inc.Methods and compositions relating to zpa polypeptidesWO2008088738A2Jan 11, 2008Jul 24, 2008Stemnion, Inc.Novel methods for modulating inflammatory and/or immune responsesWO2008127702A2Apr 11, 2008Oct 23, 2008Catalyst Biosciences, Inc.Modified factor vii polypetides and uses thereofWO2009085200A2Dec 19, 2008Jul 9, 2009Amgen Inc.Anti-amyloid antibodies and uses thereofWO2009133247A1Apr 30, 2009Nov 5, 2009Licentia OyNeurotrophic factor manf and uses thereofWO2010075249A2Dec 21, 2009Jul 1, 2010Genentech, Inc.A method for treating rheumatoid arthritis with b-cell antagonistsWO2010083841A2Jan 21, 2010Jul 29, 2010Nsgene A/SImproved cell lines and their use in encapsulated cell biodeliveryWO2010083842A2Jan 21, 2010Jul 29, 2010Nsgene A/SExpression of neuropeptides in mammalian cellsWO2010094981A2Feb 22, 2010Aug 26, 2010Fusion Antibodies LimitedAntibody therapyWO2010105068A1Mar 11, 2010Sep 16, 2010The Trustees Of The University Of PennsylvaniaOx40/trail fusion proteinsWO2010120561A1Mar 31, 2010Oct 21, 2010Genentech, Inc.Anti-fcrh5 antibodies and immunoconjugates and methods of useWO2011020049A1Aug 13, 2010Feb 17, 2011Genentech, Inc.Biological markers for monitoring patient response to vegf antagonistsWO2011028950A1Sep 2, 2010Mar 10, 2011Genentech, Inc.Mutant smoothened and methods of using the sameWO2011032013A1Sep 10, 2010Mar 17, 2011Genentech, Inc.Method to identify a patient with an increased likelihood of responding to an anti-cancer agentWO2011050194A1Oct 21, 2010Apr 28, 2011Genentech, Inc.Methods and compositions for modulating hepsin activation of macrophage-stimulating proteinWO2011063277A1Nov 19, 2010May 26, 2011Amgen Inc.Anti-orai1 antigen binding proteins and uses thereofWO2011066503A2Nov 29, 2010Jun 3, 2011Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorWO2011079185A1Dec 22, 2010Jun 30, 2011Genentech, Inc.Anti-bv8 antibodies and uses thereofWO2011106297A2Feb 22, 2011Sep 1, 2011Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorWO2011139357A1May 3, 2011Nov 10, 2011The Texas A & M University SystemAdult stem cells/progenitor cells and stem cell proteins for treatment of eye injuries and diseasesWO2011139985A1May 2, 2011Nov 10, 2011Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorWO2011146568A1May 18, 2011Nov 24, 2011Genentech, Inc.Predicting response to a her inhibitorWO2012010547A1Jul 18, 2011Jan 26, 2012F. Hoffmann-La Roche AgMethod to identify a patient with an increased likelihood of responding to an anti-cancer therapyWO2012010548A1Jul 18, 2011Jan 26, 2012F. Hoffmann-La Roche AgMethod to identify a patient with an increased likelihood of responding to an anti-cancer therapyWO2012010549A1Jul 18, 2011Jan 26, 2012F. Hoffmann-La Roche AgMethod to identify a patient with an increased likelihood of responding to an anti-cancer therapyWO2012010550A1Jul 18, 2011Jan 26, 2012F. Hoffmann-La Roche AgMethod to identify a patient with an increased likelihood of responding to an anti-cancer therapyWO2012010551A1Jul 18, 2011Jan 26, 2012F. Hoffmann-La Roche AgMethod to identify a patient with an increased likelihood of responding to an anti-cancer therapyWO2012040518A2Sep 22, 2011Mar 29, 2012Amgen Inc.Carrier immunoglobulins and uses thereofWO2012041328A1Sep 30, 2011Apr 5, 2012Nsgene A/SUse of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom painWO2012041981A2Sep 29, 2011Apr 5, 2012Laboratorios Del Dr. Esteve, S.A.Use of growth hormone to enhance the immune response in immunosuppressed patientsWO2012047968A2Oct 5, 2011Apr 12, 2012Genentech, Inc.Mutant smoothened and methods of using the sameWO2012061654A1Nov 3, 2011May 10, 2012Catalyst Biosciences, Inc.Modified factor ix polypeptides and uses thereofWO2012075184A2Nov 30, 2011Jun 7, 2012Neurotech Usa, Inc.Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereofWO2012088254A1Dec 21, 2011Jun 28, 2012Genentech, Inc.Autophagy inducer and inhibitor combination therapy for the treatment of neoplasmsWO2012145384A1Apr 18, 2012Oct 26, 2012University Of Washington Through Its Center For CommercializationBeta-2 microglobulin-deficient cellsWO2013034157A1Sep 5, 2012Mar 14, 2013Nsgene A/STreatment of allodynia, hyperalgsia, spontaneous pain, and phantom painWO2013106547A1Jan 10, 2013Jul 18, 2013President And Fellows Of Harvard CollegeBeta-cell replication promoting compounds and methods of their useWO2013148315A1Mar 15, 2013Oct 3, 2013Genentech, Inc.Diagnosis and treatments relating to her3 inhibitorsWO2013158292A1Mar 15, 2013Oct 24, 2013University Of Washington Through Its Center For CommercializationHla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereofWO2013181424A1May 30, 2013Dec 5, 2013Neurotech Usa, Inc.Cryopreserved implantable cell culture devices and uses thereofWO2014018120A1Mar 15, 2013Jan 30, 2014Catalyst Biosciences, Inc.Modified factor x polypeptides and uses thereofWO2015038669A1Sep 10, 2014Mar 19, 2015Neurotech Usa, Inc.Encapsulated cell therapy cartridgeWO2015116902A1Jan 30, 2015Aug 6, 2015Genentech, Inc.G-protein coupled receptors in hedgehog signalingWO2015120075A2Feb 4, 2015Aug 13, 2015Genentech, Inc.Mutant smoothened and methods of using the sameWO2015153514A1Mar 30, 2015Oct 8, 2015Genentech, Inc.Combination therapy comprising anti-angiogenesis agents and ox40 binding agonistsWO2016011052A1Jul 14, 2015Jan 21, 2016Genentech, Inc.Diagnostic methods and compositions for treatment of glioblastomaWO2016106340A2Dec 22, 2015Jun 30, 2016Genentech, Inc.Compositions and methods for treating and diagnosing chemotherapy-resistant cancersWO2016109546A2Dec 29, 2015Jul 7, 2016Genentech, Inc.Methods and compositions for prognosis and treatment of cancersWO2016126972A1Feb 4, 2016Aug 11, 2016Genentech, Inc.Mutant smoothened and methods of using the same* Cited by examinerClassifications U.S. Classification604/891.1, 128/898, 128/899, 424/424International ClassificationA61K9/48, A61K9/52, A61F2/02, A61M31/00, C12N11/04, A61K9/50, B01J13/02, A61K35/12, C12N5/00, A61M37/00, A61K9/00, A61K9/22, C12N5/071, C12N5/0793Cooperative ClassificationA61K35/22, C12N11/04, A61F2/022, C12N5/0619, A61K9/0092, A61M2210/0693, C12N2533/30, A61M2210/0687, C12N5/0012, A61K9/0085, A61K35/30, B01J13/02, C12N5/0614, A61K9/0024, A61M31/002European ClassificationC12N5/00C, A61K9/00M22, A61F2/02B, A61K9/00Z4, B01J13/02, C12N11/04, C12N5/06B7A, C12N5/06B8A, A61K9/00M5D, A61K35/12, A61M31/00DLegal EventsDateCodeEventDescriptionNov 17, 1987ASAssignmentOwner name: BROWN UNIVERSITY RESEARCH FOUNDATION, BROWN UNIVERFree format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:AEBISCHER, PATRICK;WINN, SHELLEY R.;GALLETTI, PIERRE M.;REEL/FRAME:004811/0488Effective date: 19871113Jan 1, 1991CCCertificate of correctionJul 2, 1993FPAYFee paymentYear of fee payment: 4Aug 24, 1993RFReissue application filedEffective date: 19930630Apr 28, 1997FPAYFee paymentYear of fee payment: 8Dec 12, 2005ASAssignmentOwner name: NEUROTECH S.A., FRANCEFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CYTOTHERAPEUTICS, INC.;REEL/FRAME:017073/0187Effective date: 19991229Apr 5, 2006ASAssignmentOwner name: NEUROTECH S.A., FRANCEFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CYTOTHERAPEUTICS, INC.;REEL/FRAME:017794/0001Effective date: 19991229RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services


text:
Rodgers gamble backfires as Liverpool lose to Chelsea | Daily Mail Online
Rodgers gamble backfires as Liverpool lose to Chelsea
Published: 12:13 EST, 8 November 2014 | Updated: 12:13 EST, 8 November 2014
LIVERPOOL, England, Nov 8 (Reuters) - Liverpool manager Brendan Rodgers was adamant that he did not regret his team selection despite falling to a fifth Premier League defeat against table-topping Chelsea on Saturday.
Rodgers restored seven first-choice players to the team, dropping several of the stand-out players who had performed creditably in the makeshift side which lost to Real Madrid on Tuesday.
The decision to rest so many key players had led to much criticism of Rodgers, with accusations that he had belittled both the Champions League and the club's proud reputation in a competition they have won five times.
But Rodgers said he stood by the decision to leave out his main men and then to restore them, even though they once again under-performed as Liverpool slipped to a 2-1 defeat by Chelsea, a defeat which left them 15 points behind the leaders.
"I wouldn't have done anything differently at all," Rodgers told a news conference when asked whether, in hindsight, he would have selected the same teams against Real Madrid and Chelsea.
Yet audible displeasure from a section of Liverpool fans following the decision to substitute Emre Can and Philippe Coutinho hinted at growing dissatisfaction.
"Of course, the supporters are frustrated with the team losing three games on the spin and that is something they are not used to so I completely understand that," said Rodgers.
Much of the frustration among Liverpool supporters stems from the team's struggles in front of goal. They scored 101 goals in the Premier League last season but following the sale of Luis Suarez and the injury to Daniel Sturridge, they have only managed 14 goals in 11 league matches.
Rodgers did have encouraging news for the fans, however, saying he hoped to have Sturridge back in the starting line-up for the game at Crystal Palace in two weeks.

type: global

value: This website is the website of the Daily Mail, a newspaper in the United Kingdom, and of its sister paper The Mail on Sunday. MailOnline is a division of dmg media, which is owned by Daily Mail and General Trust plc.


text:
Hey Guys, long time no see...A couple from the Leica M and Noctolux: Leica Talk Forum: Digital Photography Review
Forum indexLeica TalkChange forum Hey Guys, long time no see...A couple from the Leica M and Noctolux
Hey Guys, long time no see...A couple from the Leica M and Noctolux Feb 10, 2014
A couple of night shots with the Leica M 240 and Noctolux shot wide open at 0.95.
Got to take only this lens and camera on a recent trip to Florida, and wise nice to leave all other cameras and lenses behind.
Post (hide subjects)Posted byWhenHey Guys, long time no see...A couple from the Leica M and NoctoluxNew(unknown member) Feb 10, 20141

value: This website is a website about digital cameras and digital photography, established in November 1998. The website provides comprehensive reviews of digital cameras, lenses and accessories, buying guides, user reviews, and forums for individual cameras, as well as general photography forums.


text:
Internet Archive Search: mediatype:movies AND subject:"Earthly Behaviours With Dr. Walt: The Search For Extraterrestrial Life"
1 RESULTS Media Type 1 movies Availability 1 Always Available Topics & Subjects 1 Earthly Behaviours with Dr. Walt: The Search for Extraterrestrial Life Collection 1 The Community Media Archive 1 Mendocino Coast Television (MCTV) Creator 1 mctv SHOW DETAILS
favorite 0 comment 0 Earthly Behaviours with Dr. Walt: The Search for Extraterrestrial Life Topic: Earthly Behaviours with Dr. Walt: The Search for Extraterrestrial Life MORE RESULTS

value: This website is an American digital library with the stated mission of "universal access to all knowledge". It provides free public access to collections of digitized materials, including websites, software applications/games, music, movies/videos, moving images, and millions of books.


text:
Find out if your remodeling dreams fit your budget reality.Try the Real Cost Finder 98,111 living-wall Modern Home Design Photos
Ideabooks5,084	Questions2	contrast, brick wall, sofa wall, etc.White brick wall...White brick walls....living & dining...Living room...Wall sconces by tv...rug, black wall, cool table...White brick wall living room...Brick wall *...Size of living roomrug, black wall, cool table — carlamercer Embed
Ideabooks10,265	Questions9	I want to remove my curtains from the dining/living room in my very small apt. Curtains make the room look messy and crowdedAccent wall paint color please? Perfect balance. Thanks!Masterbed room plain wall tv console areaquaint studio. With living room and desk.How about queen size platform bed turned sideways against the back wall. Cypress headboard builtof the long, narrow space. The dark accent wall recedes, making the space appear a bit bigger, but the wall color also helps the office accessories andand a desk. If they're not careful, I just might move in. The deep brown wall helps to make the room seem longer than it really is.
How do you make yourwhat is the accent wall color?...Tv and office wall Wall colorDark wall — mollykuhl Embed
Ideabooks33,649	Questions25	of flooring used in the kitchen and living room?you tell me the wall color and brand? Thanks!Are you aware of the floor deminions of the sunken living room?can you please tell me the color of the walls - what specific paint was used? Thank youis one of the nicer living rooms that I have designed. Thanks for the kind words.
Charles Todd Helton, ArchitectLove the table in living room, where could you buy itVery impressive! Is that Realstone by the bar stools and stairs wall?love the split face stone on the bar and wall - what is the name of the product that was used to achieve this look?plan, mix of natural wood with white walls and ceilings, perfect placement of doors and windows, steps down to living room area. Modern/mid century designWant them for my living room...this living room rocks! do you knowLevels — Kerry Holmes Embed
Ideabooks2,247	Questions9	What color is the paint on the back wall?Sorry I didn't get back to you sooner. The plywood paneling over the fireplace and on the side wall is surfacedyour help and i will give you a call when we get closer to finishing our living room addition. Thanks again!!!There is a local showroom that shows the rugs if you are interested and live in the Twin Cities.
PatGreyhound Chair and Ottoman. See it on this link to the web page - .... If you live in the Twin Cities area of Minnesota you could stop by our showroom to seemake outside kitchen wall of the living room wood like hereLove the artwork on the right hand wall...the back wall and into the dining room....Feature wall above fireplace no mantleMid century modern — kcmzajd Embed
Ideabooks15,216	Questions10	What is on the accent wall? Rex tile in horn?Can you describe the technique used on the wall behind the bed?there is grout between the tiles on the wall?I love, love, love this wall. What is it madeReplicating the beautiful wall...The wall is "Rex Horn" tile...bed room with living space....Wall idea...wall design...Suggestion for wall paper...bed wall...Back wall...Wall covering...Marble wall...Accent wall...The wall...Tile wall...cool wall...Wall and floors...the walls...the wood wall...Wall paint...Like the wall...Nice feature wall for bedroom...Nice walllarge tile for bedroom — Line Green Embed
Ideabooks4,769	Questions4	Please tell me where I can get this wall mural of the telephone wires?That wall sticker is fab! The colours of the furniture andLive the dreamIt doesn’t take much to turn a blank wall into a reverie-inducing image. This simple wall sticker is both evocativeWall DecalsThey are great for people who can't or don't want to commit to wallpaperwallpaper. And they are certainly a lot less expensive than art. But does the wall decal mural have a future?look like that on your wall!...The wall decal was purchased attelephone wire art — dafjt Embed
Ideabooks19,514	Questions15	flows of volumes and spaces, and incorporates large areas of indoor/outdoor living on both levels.
Taking aging in place into consideration, there are masterwhat are the light gray and dark gray wall colors?I love the tv/wall unit, is it available in U.K?What are the 2 paint colours used on the wall and in the inset area?living room. check out the ceiling.dnevna — majamanevski Embed
Ideabooks2,903	Questions3	corrosion of my external rammed earth walls and some internal. Can u recommend a good sealer? How are your external walls holding up? Were they capped?you avoid having to put a pool fence at the edge nearest the rammed earth wall. I want to do the same in a new build, and am coming across all sorts ofdoing only one wall is a tiny job so would incur an additional cost I imagine. I hope that's been helpful.roughly how much would a wall cost to buildLove this house with the rammed earth walls and solar panelsthe change in direction on the building. the slide up and down exterior windows.The use of glass for external wallindoor living spaces out into the landscape via decks, a vegetable patch, lawn areas, a cricket pitch and a 25-metre lap pool. In this way, living on theWall of glass, opening glass wallopen, cement wall, pool!!!!! — francesca122 Embed
Modern Products Related to "Living Wall" Cherish yesterday dream tomorrow live today Wall Decal
$58.50 Forest Trees Mural
$182 Long Live Art Wall Art
$240 Love Live Laugh Wall Art
$850 Trenton Corner Shelf 14"
$43 212223242526272829Next Page Embed photo

value: This website is an American website, online community and software for architecture; interior design and decorating; landscape design and home improvement. It was founded in 2009 and is based in Palo Alto, California.


text:
rapid reaction 2 - AFC West Blog - ESPN
AFC West: rapid reaction 2
Rapid reaction: Broncos 39, Chargers 38
Posted by ESPN.com's Bill Williamson DENVER -- Mike Shanahan has some major guts. And he has some major offensive talents. Ending a classic NFL September game, Shanahan ordered his young gun quarterback to go for two points with 24 seconds to go after Denver, which squandered a 21-3 lead, came back to pull within 38-37 after Jay Cutler hit rookie sensation Eddie Royal on fourth and goal from the 4-yard line. With the Denver crowd stunned as the home team passed up the chance to tie, the rare two-point conversion to win the game worked as Cutler hit Royal for the score. Suddenly, the Broncos are 2-0 and the Chargers are 0-2. By the way, Denver star receiver Brandon Marshall caught 18 passes. With Cutler, Marshall and Royal the Broncos have the talent to make along run in the AFC West. And we all know they have a coach with the gumption to handle it.
Tags:Eddie Royal, Jay Cutler, Brandon Marshall, Chargers-Broncos, Mike Shanahan, rapid reaction 2

value: This website is the official website of ESPN. It is owned by ESPN Internet Ventures, a division of ESPN Inc.


text:
BBC World Service - BBC News, 25/01/2014 - QR code The BBC has updated its cookie policy. We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites if you visit a page which contains embedded content from social media. Such third party cookies may track your use of the BBC website. We and our partners also use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the BBC website. However, you can change your cookie settings at any time. Continue Change settings Find out more ]]> Accessibility links Skip to content Accessibility Help BBC iD BBC navigation News News Sport Weather Radio Arts Menu Search the BBC
BBC News HomeEpisodesClipsAfrica Today PodcastSubscribe to our Newsletter Join us on FacebookFollow us on Twitter BBC News, 25/01/2014 QR code What is this? A QR code is a type of barcode which can contain links to webpages. Mobile phones with a camera and an appropriate application are able to read these codes and take you to the address contained within it. This code will link to the page for BBC News, 25/01/2014 when read using a QR code reader. You may save, print or share the image. You may also like View all Similar programmes By genre: News HomeOnline scheduleProgrammesDownloadsHelp & FAQsContact usNews in 27 languages {{/each}}

value: This website is the BBC's online service. It is a large network of websites including such high-profile sites as BBC News and Sport, the on-demand video and radio services co-branded BBC iPlayer, the children's sites CBBC and CBeebies, and learning services such as Bitesize.